<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:48.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Review Article</span></p>
<p style="top:80.9pt;left:49.6pt;line-height:18.0pt"><span style="font-family:AdvP7D0F,serif;font-size:18.0pt">Glucagon-like peptide-1 receptor</span></p>
<p style="top:100.9pt;left:49.6pt;line-height:18.0pt"><span style="font-family:AdvP7D0F,serif;font-size:18.0pt">agonists as neuroprotective agents for</span></p>
<p style="top:120.9pt;left:49.6pt;line-height:18.0pt"><span style="font-family:AdvP7D0F,serif;font-size:18.0pt">ischemic stroke: a systematic scoping</span></p>
<p style="top:140.9pt;left:49.6pt;line-height:18.0pt"><span style="font-family:AdvP7D0F,serif;font-size:18.0pt">review</span></p>
<p style="top:194.9pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Mark P Maskery</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">1,2</span></sup></p>
<p style="top:194.9pt;left:165.3pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">, Christian Holscher</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">3</span></sup></p>
<p style="top:194.9pt;left:294.9pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">,</span></p>
<p style="top:208.9pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Stephanie P Jones</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">4</span></sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">, Christopher I Price</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">5</span></sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">, W David Strain</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">6</span></sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">,</span></p>
<p style="top:222.9pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Caroline L Watkins</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">4</span></sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">, David J Werring</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">7</span></sup><sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">and</span></p>
<p style="top:236.9pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Hedley CA Emsley</span><sup><span style="font-family:AdvP7D0F,serif;font-size:8.5pt">1,2</span></sup></p>
<p style="top:286.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Abstract</span></p>
<p style="top:298.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acute ischemic stroke</span></p>
<p style="top:310.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">treatment, scope remains for development of widely applicable neuroprotective agents. Glucagon-like peptide-1 recep-</span></p>
<p style="top:322.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">tor agonists (GLP-1RAs), originally licensed for the management of Type 2 Diabetes Mellitus, have demonstrated pre-</span></p>
<p style="top:334.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">clinical neuroprotective efficacy in a range of neurodegenerative conditions. This systematic scoping review reports the</span></p>
<p style="top:346.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">pre-clinical basis of GLP-1RAs as neuroprotective agents in acute ischemic stroke and their translation into clinical trials.</span></p>
<p style="top:358.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">We included 35 pre-clinical studies, 11 retrospective database studies, 7 cardiovascular outcome trials and 4 prospective</span></p>
<p style="top:370.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">clinical studies. Pre-clinical neuroprotection was demonstrated in normoglycemic models when administration was</span></p>
<p style="top:382.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">delayed by up to 24 h following stroke induction. Outcomes included reduced infarct volume, apoptosis, oxidative</span></p>
<p style="top:394.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">stress and inflammation alongside increased neurogenesis, angiogenesis and cerebral blood flow. Improved neurological</span></p>
<p style="top:406.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">function and a trend towards increased survival were also reported. Cardiovascular outcomes trials reported a signif-</span></p>
<p style="top:418.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">icant reduction in stroke incidence with semaglutide and dulaglutide. Retrospective database studies show a trend</span></p>
<p style="top:430.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">towards neuroprotection. Prospective interventional clinical trials are on-going, but initial indicators of safety and</span></p>
<p style="top:442.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">tolerability are favourable. Ultimately, we propose that repurposing GLP-1RAs is potentially advantageous but appro-</span></p>
<p style="top:454.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">priately designed trials are needed to determine clinical efficacy and cost-effectiveness.</span></p>
<p style="top:484.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Keywords</span></p>
<p style="top:496.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Acute stroke, neuroprotection, reperfusion, clinical trials, animal models</span></p>
<p style="top:515.6pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Received 2 January 2020; Accepted 18 July 2020</span></p>
<p style="top:555.4pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Introduction</span></p>
<p style="top:574.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke accounts for 6.5 million deaths per year globally</span></p>
<p style="top:586.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and by 2030 will result in an annual loss of over 200</span></p>
<p style="top:599.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">million disability-adjusted life years.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">1,2</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">With an increas-</span></p>
<p style="top:611.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing number of strokes occurring in younger patients,</span></p>
<p style="top:624.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">alongside an increased number of stroke survivors, the</span></p>
<p style="top:636.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cost of post-stroke care is rising. There is, therefore,</span></p>
<p style="top:649.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">signi&#xfb01;cant scope to improve upon the current position.</span></p>
<p style="top:661.0pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Considerable advances have been made in acute</span></p>
<p style="top:673.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ischemic stroke (AIS) treatment, notably reperfusion</span></p>
<p style="top:685.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">therapies, but these are limited to 10&#x2013;20% of total</span></p>
<p style="top:698.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke patients following careful clinical and radiolog-</span></p>
<p style="top:710.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ical selection.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">3</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Even when intravenous thrombolysis</span></p>
<p style="top:723.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and/or endovascular thrombectomy are administered,</span></p>
<p style="top:533.8pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">1</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Lancaster Medical School, Lancaster University, Lancaster, UK</span></p>
<p style="top:543.9pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">2</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Department of Neurology, Royal Preston Hospital, Preston, UK</span></p>
<p style="top:553.8pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">3</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Research and Experimental Center, Henan University of Chinese</span></p>
<p style="top:565.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Medicine, Zhengzhou, Henan Province, China</span></p>
<p style="top:573.9pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">4</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Faculty of Health and Wellbeing, University of Central Lancashire,</span></p>
<p style="top:585.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Preston, UK</span></p>
<p style="top:593.9pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">5</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Institute of Neuroscience, Stroke Research Group, Newcastle</span></p>
<p style="top:605.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">University, Newcastle, UK</span></p>
<p style="top:613.9pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">6</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">NIHR Exeter Clinical Research Facility and Institute of Biomedical and</span></p>
<p style="top:625.6pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Clinical Science, University of Exeter Medical School, Royal Devon &amp;</span></p>
<p style="top:635.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Exeter NHS Foundation Trust, Exeter, UK</span></p>
<p style="top:643.9pt;left:297.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">7</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Stroke Research Centre, Department of Brain Repair and Rehabilitation,</span></p>
<p style="top:655.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">UCL Institute of Neurology and The National Hospital for Neurology</span></p>
<p style="top:665.5pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">and Neurosurgery, London, UK</span></p>
<p style="top:684.9pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D0F,serif;font-size:8.0pt">Corresponding author:</span></p>
<p style="top:694.9pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Mark Maskery, Department of Neurology, Royal Preston Hospital,</span></p>
<p style="top:704.9pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Lancashire Teaching Hospitals NHS Foundation Trust, Sharoe Green</span></p>
<p style="top:715.0pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Lane, Preston PR2 9HT, UK.</span></p>
<p style="top:724.9pt;left:297.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Email: Mark.Maskery@doctors.org.uk</span></p>
<p style="top:72.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Journal of Cerebral Blood Flow &amp;</span></p>
<p style="top:81.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Metabolism</span></p>
<p style="top:90.2pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2021, Vol. 41(1) 14&#x2013;30</span></p>
<p style="top:99.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP42A1B7,serif;font-size:7.0pt">!</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> The Author(s) 2020</span></p>
<p style="top:108.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Article reuse guidelines:</span></p>
<p style="top:117.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">sagepub.com/journals-permissions</span></p>
<p style="top:126.2pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DOI: 10.1177/0271678X20952011</span></p>
<p style="top:135.1pt;left:434.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">journals.sagepub.com/home/jcbfm</span></p>
<img style="position:absolute;transform:matrix(.374269,0,-0,.3851852,-38,-6.6653645)" src="data:image/png;base64,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">


<p style="top:72.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction in disability is highly time dependent.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">4,5</span></sup></p>
<p style="top:84.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Scope remains for further improvement, especially for</span></p>
<p style="top:96.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">patients who are unsuitable for reperfusion therapies or</span></p>
<p style="top:109.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those within remote environments.</span></p>
<p style="top:121.0pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Using simpler clinical selection processes, neuropro-</span></p>
<p style="top:133.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tective therapies could bring bene&#xfb01;ts to a wider patient</span></p>
<p style="top:145.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">group. Neuroprotectants could also enhance the bene-</span></p>
<p style="top:157.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;ts of reperfusion therapies by preservation of the</span></p>
<p style="top:169.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ischemic penumbra and reduction in ischemic reperfu-</span></p>
<p style="top:181.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sion injury. Despite many demonstrating pre-clinical</span></p>
<p style="top:193.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">potential, a suitable agent has not yet been identi&#xfb01;ed</span></p>
<p style="top:205.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by translational studies.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">6</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">There remains a multitude of</span></p>
<p style="top:217.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">factors affecting the translation from bench-to-bedside.</span></p>
<p style="top:229.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Namely, animal models are not perfect in their repre-</span></p>
<p style="top:241.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sentation of the heterogeneity of clinical stroke.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">7</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke</span></p>
<p style="top:253.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:253.5pt;left:81.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">humans</span></p>
<p style="top:253.5pt;left:125.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">occurs</span></p>
<p style="top:253.5pt;left:163.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:253.5pt;left:182.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:253.5pt;left:205.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">context</span></p>
<p style="top:253.5pt;left:247.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:253.5pt;left:267.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ageing,</span></p>
<p style="top:265.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">co-morbidity (hypertension, diabetes mellitus, atrial</span></p>
<p style="top:277.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;brillation, pre-existing cerebrovascular disease) and</span></p>
<p style="top:289.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">concomitant medication use.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">8</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Furthermore, factors</span></p>
<p style="top:301.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">such as gender, cerebral blood &#xfb02;ow, body temperature</span></p>
<p style="top:313.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and glycemic status may in&#xfb02;uence stroke mechanism</span></p>
<p style="top:325.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and outcomes associated with therapy.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">6,9&#x2013;11</span></sup></p>
<p style="top:337.8pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Glucagon-Like Peptide-1 (GLP-1) receptor agonists</span></p>
<p style="top:349.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are gaining increasing momentum as possible neuro-</span></p>
<p style="top:361.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protective agents in AIS. GLP-1 is an incretin hor-</span></p>
<p style="top:374.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mone. Alongside its role in insulin secretion from the</span></p>
<p style="top:386.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pancreas and glucagon suppression, it also crosses the</span></p>
<p style="top:398.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blood-brain barrier (BBB) and promotes synaptic func-</span></p>
<p style="top:410.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion, enhances neurogenesis, reduces apoptosis and</span></p>
<p style="top:422.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protects neurons from oxidative stress.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">12</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1 is pro-</span></p>
<p style="top:434.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">duced in the brain and receptors are distributed</span></p>
<p style="top:446.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">throughout</span></p>
<p style="top:446.3pt;left:119.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:446.3pt;left:141.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">central</span></p>
<p style="top:446.3pt;left:178.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nervous</span></p>
<p style="top:446.3pt;left:221.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">system.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">13</span></sup></p>
<p style="top:446.3pt;left:268.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1</span></p>
<p style="top:458.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Receptor Agonists (GLP-1RAs), licensed for Type 2</span></p>
<p style="top:470.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Diabetes Mellitus (T2DM) have already demonstrated</span></p>
<p style="top:482.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pre-clinical neuroprotective ef&#xfb01;cacy in Alzheimer&#x2019;s</span></p>
<p style="top:494.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Disease and clinical trials in neurodegenerative condi-</span></p>
<p style="top:506.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tions are ongoing.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">12,14</span></sup></p>
<p style="top:518.5pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The aim of this systematic scoping review is to</span></p>
<p style="top:530.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">report the pre-clinical basis of GLP-1RAs as neuropro-</span></p>
<p style="top:542.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tective agents in AIS and their translation into clinical</span></p>
<p style="top:554.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trials. In addition to describing the characteristics and</span></p>
<p style="top:566.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">quality of studies, the objectives are to speci&#xfb01;cally con-</span></p>
<p style="top:578.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sider timing of administration, association with glyce-</span></p>
<p style="top:590.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mic status, neuroprotective outcomes and application</span></p>
<p style="top:602.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to clinical care.</span></p>
<p style="top:630.7pt;left:62.4pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Materials and methods</span></p>
<p style="top:653.1pt;left:62.4pt;line-height:12.0pt"><span style="font-family:AdvP7D0C,serif;font-size:12.0pt">Eligibility criteria</span></p>
<p style="top:672.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Pre-clinical: We included pre-clinical</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> in vivo</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> studies</span></p>
<p style="top:684.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">which administered naturally occurring GLP-1, a</span></p>
<p style="top:696.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mimetic or analogue, before, during or after stroke</span></p>
<p style="top:708.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">induction. Normoglycemic, hyperglycemic and induced</span></p>
<p style="top:721.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">T2DM models were included.</span></p>
<p style="top:72.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Studies were excluded if their only focus was hem-</span></p>
<p style="top:85.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">orrhagic stroke as this does not re&#xfb02;ect the proposed</span></p>
<p style="top:97.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mechanism for how GLP-1 is involved in ischemic</span></p>
<p style="top:110.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tissue injury. Those studies which reported incidence</span></p>
<p style="top:122.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of hemorrhagic transformation as a complication of</span></p>
<p style="top:134.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AIS</span></p>
<p style="top:134.8pt;left:337.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:134.8pt;left:366.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">included</span></p>
<p style="top:134.8pt;left:412.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as</span></p>
<p style="top:134.8pt;left:431.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">these</span></p>
<p style="top:134.8pt;left:462.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">re&#xfb02;ect</span></p>
<p style="top:134.8pt;left:497.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">post-stroke</span></p>
<p style="top:147.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">complications.</span></p>
<p style="top:159.2pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical: We included all prospective clinical trials</span></p>
<p style="top:171.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">which administered GLP-1RAs before, during or</span></p>
<p style="top:184.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">after stroke onset with outcome measures de&#xfb01;ned to</span></p>
<p style="top:196.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">identify neuroprotective ef&#xfb01;cacy by way of stroke</span></p>
<p style="top:208.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">volume reduction or improvement in post-stroke func-</span></p>
<p style="top:221.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion or mortality. We also included any potential fea-</span></p>
<p style="top:233.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sibility or safety-based studies in this area.</span></p>
<p style="top:245.5pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Our scoping searches identi&#xfb01;ed that very few pro-</span></p>
<p style="top:257.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spective clinical trials measuring stroke outcomes were</span></p>
<p style="top:270.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">available. Pragmatically, we therefore also included all</span></p>
<p style="top:282.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">retrospective database analyses of stroke incidence or</span></p>
<p style="top:295.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">composite cardiovascular outcomes in patients treated</span></p>
<p style="top:307.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with GLP-1RAs. Furthermore, we included cardiovas-</span></p>
<p style="top:319.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cular outcome trials (CVOTs) of GLP-1RAs to evalu-</span></p>
<p style="top:332.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ate the incidence of stroke in this relatively higher risk</span></p>
<p style="top:344.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cohort.</span></p>
<p style="top:356.7pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Studies were excluded if their full-text was not avail-</span></p>
<p style="top:369.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">able or not published in English. Efforts were made to</span></p>
<p style="top:381.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">contact authors directly to obtain any missing articles</span></p>
<p style="top:393.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or data.</span></p>
<p style="top:417.8pt;left:310.4pt;line-height:12.0pt"><span style="font-family:AdvP7D0C,serif;font-size:12.0pt">Database search strategy</span></p>
<p style="top:436.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">After several initial scoping searches,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">15</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">we accessed</span></p>
<p style="top:448.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Web</span></p>
<p style="top:448.7pt;left:338.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:448.7pt;left:356.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Science</span></p>
<p style="top:448.7pt;left:396.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on</span></p>
<p style="top:448.7pt;left:416.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">19</span></p>
<p style="top:448.7pt;left:435.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">March</span></p>
<p style="top:448.7pt;left:472.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2020</span></p>
<p style="top:448.7pt;left:501.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to</span></p>
<p style="top:448.7pt;left:518.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">search</span></p>
<p style="top:461.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MEDLINE, Web of Science core collection, BIOSIS</span></p>
<p style="top:473.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and SciELO from 1 January 2000. Keywords were</span></p>
<p style="top:485.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EITHER &#x2018;GLP(-)1, glucagon like peptide(-)1, exena-</span></p>
<p style="top:498.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tide, liraglutide, lixisenatide, albiglutide, dulaglutide,</span></p>
<p style="top:510.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">semaglutide&#x2019; AND EITHER &#x2018;stroke, CVA, cerebrovas-</span></p>
<p style="top:523.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cular, h(a)emorrhage, small vessel disease&#x2019;. Articles</span></p>
<p style="top:535.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were cross-referenced and references were searched to</span></p>
<p style="top:547.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">identify further studies of interest.</span></p>
<p style="top:559.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">All articles/studies were screened independently in</span></p>
<p style="top:572.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">an unblinded, standardised manner by MM and HE</span></p>
<p style="top:584.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by way of title and abstract to identify those suitable</span></p>
<p style="top:597.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for full-text review. Queries and disagreements were</span></p>
<p style="top:609.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resolved by discussion. Preferred Reporting Items for</span></p>
<p style="top:621.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Systematic Reviews and Meta-Analyses (PRISMA)</span></p>
<p style="top:634.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">guidelines</span></p>
<p style="top:634.2pt;left:361.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:634.2pt;left:389.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">applied.</span></p>
<p style="top:634.2pt;left:432.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Pre-clinical</span></p>
<p style="top:634.2pt;left:488.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:634.2pt;left:525.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:646.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">appraised according to Animal Research: Reporting</span></p>
<p style="top:659.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of In Vivo Experiments (ARRIVE) guidelines,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">16</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:671.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:671.4pt;left:332.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">updated</span></p>
<p style="top:671.4pt;left:376.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke</span></p>
<p style="top:671.4pt;left:413.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Therapy</span></p>
<p style="top:671.4pt;left:458.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Academic</span></p>
<p style="top:671.4pt;left:509.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Industry</span></p>
<p style="top:683.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Roundtable Preclinical Recommendations (STAIR)</span></p>
<p style="top:696.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">guidelines.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">7</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Data supporting the &#xfb01;ndings of this</span></p>
<p style="top:708.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">review are available from the corresponding author</span></p>
<p style="top:721.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">upon reasonable request.</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">15</span></p>


<p style="top:72.5pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Results</span></p>
<p style="top:94.9pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0C,serif;font-size:12.0pt">Study selection</span></p>
<p style="top:114.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The literature search identi&#xfb01;ed 797 results (see Figure 1)</span></p>
<p style="top:127.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">alongside 10 from other sources. After removal of dupli-</span></p>
<p style="top:139.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cates, this left 794 for screening. We excluded 593</span></p>
<p style="top:151.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">articles based upon title and review of abstract leaving</span></p>
<p style="top:164.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">201 full text articles to review. In total, 35 preclinical</span></p>
<p style="top:176.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies, 11 retrospective database studies, 7 cardiovascu-</span></p>
<p style="top:189.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lar outcome trials and 4 prospective clinical studies met</span></p>
<p style="top:201.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the inclusion criteria.</span></p>
<p style="top:225.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Pre-clinical studies</span></p>
<p style="top:237.7pt;left:61.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Characteristics of included studies.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> As shown in</span></p>
<p style="top:250.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Table 1, 35 pre-clinical studies were included within</span></p>
<p style="top:262.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this review. Studies were completed between 2009 and</span></p>
<p style="top:275.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2020. Studies were predominantly based upon mouse</span></p>
<p style="top:287.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and rat models of stroke; however, one study utilised a</span></p>
<p style="top:299.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gerbil model.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">17</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke induction was either via tran-</span></p>
<p style="top:312.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sient (range 30&#x2013;120 min) or permanent common carot-</span></p>
<p style="top:324.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">id</span></p>
<p style="top:324.8pt;left:66.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(CCAO)</span></p>
<p style="top:324.8pt;left:111.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or</span></p>
<p style="top:324.8pt;left:129.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">middle</span></p>
<p style="top:324.8pt;left:167.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cerebral</span></p>
<p style="top:324.8pt;left:210.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">artery</span></p>
<p style="top:324.8pt;left:244.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">occlusion</span></p>
<p style="top:337.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(MCAO). Most studies induced unilateral occlusion</span></p>
<p style="top:349.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in keeping with spontaneously occurring stroke onset</span></p>
<p style="top:362.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in humans, but six studies utilised a bilateral occlusion</span></p>
<p style="top:374.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">model. Cerebral ischemia was induced by either liga-</span></p>
<p style="top:387.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion, &#xfb01;lament occlusion or ablation of the relevant</span></p>
<p style="top:399.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">artery.</span></p>
<p style="top:72.8pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Twelve studies administered exendin-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">17&#x2013;28</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">nine</span></p>
<p style="top:85.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">used liraglutide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29&#x2013;37</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">three used rhGLP-1 (recombinant</span></p>
<p style="top:97.1pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">human GLP-1),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">38&#x2013;40</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">three used lixisenatide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">41&#x2013;43</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:109.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">one study each reported the utility of semaglutide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup></p>
<p style="top:121.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PEx-4</span></p>
<p style="top:121.3pt;left:338.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(exendin-4</span></p>
<p style="top:121.3pt;left:397.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">loaded</span></p>
<p style="top:121.3pt;left:441.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">poly-microspheres),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">44</span></sup></p>
<p style="top:133.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proGLP-1 (long acting GLP-1RA),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">45</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">DMB (GLP-1R</span></p>
<p style="top:145.5pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">agonist/modulator),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">46</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">dual GLP-1/Glucose-dependent</span></p>
<p style="top:157.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Insulinotropic</span></p>
<p style="top:157.7pt;left:366.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Peptide</span></p>
<p style="top:157.7pt;left:406.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(GIP)</span></p>
<p style="top:157.7pt;left:439.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">agonist</span></p>
<p style="top:157.7pt;left:478.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(GLP-1/GIP</span></p>
<p style="top:169.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">DA),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">47</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">oxyntomodulin (co-activates GLP-1R and glu-</span></p>
<p style="top:181.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cagon receptor),</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">48</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">P7C3 (aminopropyl carbazole com-</span></p>
<p style="top:194.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pound)</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">49</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and one study directly compared exendin-4</span></p>
<p style="top:206.1pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with liraglutide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">In eight studies, GLP-1R antago-</span></p>
<p style="top:218.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nists, such as Ex-9-39, were administered to study the</span></p>
<p style="top:230.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">role</span></p>
<p style="top:230.3pt;left:323.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:230.3pt;left:340.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:230.3pt;left:362.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1R</span></p>
<p style="top:230.3pt;left:408.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:230.3pt;left:425.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroprotective</span></p>
<p style="top:230.3pt;left:502.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mecha-</span></p>
<p style="top:242.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nisms.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">19,21&#x2013;23,41,45,46,49</span></sup></p>
<p style="top:254.4pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Two studies investigated multiple doses of GLP-</span></p>
<p style="top:266.5pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1RAs to compare neuroprotective ef&#xfb01;cacy and con-</span></p>
<p style="top:278.6pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cluded that neuroprotection was dose-dependent.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">20,51</span></sup></p>
<p style="top:290.7pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Most studies administered GLP-1RAs via intraper-</span></p>
<p style="top:302.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">itoneal, subcutaneous or transvenous routes. However,</span></p>
<p style="top:314.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Zhang et al. reported neuroprotection with both oral</span></p>
<p style="top:327.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">DMB</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">46</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and intranasal exendin-4.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">22</span></sup></p>
<p style="top:339.0pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Some 14 studies administered GLP-1RAs chroni-</span></p>
<p style="top:351.1pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cally prior to the onset of stroke. Clinically, this</span></p>
<p style="top:363.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">would represent those patients who receive GLP-</span></p>
<p style="top:375.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1RAs</span></p>
<p style="top:375.3pt;left:331.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as</span></p>
<p style="top:375.3pt;left:350.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">part</span></p>
<p style="top:375.3pt;left:377.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:375.3pt;left:396.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">routine</span></p>
<p style="top:375.3pt;left:437.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">T2DM</span></p>
<p style="top:375.3pt;left:476.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">management</span></p>
<p style="top:387.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and then go on to experience AIS.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">18,19,22,23,29,31,38,</span></sup></p>
<p style="top:397.4pt;left:297.6pt;line-height:7.1pt"><span style="font-family:Times New Roman,serif;font-size:7.1pt">39,42,44&#x2013;46,48,51</span></p>
<p style="top:399.6pt;left:370.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Chronic</span></p>
<p style="top:399.6pt;left:420.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pre-treatment</span></p>
<p style="top:399.6pt;left:494.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">occurred</span></p>
<img style="position:absolute;transform:matrix(.54847767,0,-0,.54820516,20.52069,431.1333)" src="data:image/png;base64,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">
<p style="top:720.1pt;left:49.6pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Figure 1.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> PRISMA flow chart demonstrating the selection of studies.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">16</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:721.8pt;left:62.0pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 1.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Overview of the pre-clinical studies.</span></p>
<p style="top:723.4pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Author</span></p>
<p style="top:667.1pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Year</span></p>
<p style="top:647.6pt;left:97.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Animal</span></p>
<p style="top:647.6pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">model</span></p>
<p style="top:622.4pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Co-morb.</span></p>
<p style="top:588.7pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Drug</span></p>
<p style="top:531.4pt;left:97.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Admin</span></p>
<p style="top:531.4pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">route</span></p>
<p style="top:507.1pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Sub-studies</span></p>
<p style="top:416.0pt;left:88.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Stroke</span></p>
<p style="top:416.0pt;left:97.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">induction</span></p>
<p style="top:416.0pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(time/min)</span></p>
<p style="top:354.6pt;left:79.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Administration time (min)</span></p>
<p style="top:354.6pt;left:97.0pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Pre-</span></p>
<p style="top:354.6pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:306.7pt;left:97.0pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Post-</span></p>
<p style="top:306.7pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:220.7pt;left:106.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Main outcomes (NP &#x2013; Neuroprotective)</span></p>
<p style="top:723.4pt;left:122.9pt;line-height:7.0pt"><span style="font-family:AdvP7D12,serif;font-size:7.0pt">GLP-1RA administered prior to stroke onset (including chronic pre-treatment)</span></p>
<p style="top:723.4pt;left:130.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Li et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">18</span></p>
<p style="top:667.1pt;left:131.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2009 Rat</span></p>
<p style="top:588.7pt;left:131.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:131.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.c.v.</span></p>
<p style="top:416.0pt;left:131.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l tMCAO (60)</span></p>
<p style="top:354.6pt;left:131.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">15</span></p>
<p style="top:220.7pt;left:131.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume and improves functional</span></p>
<p style="top:211.7pt;left:140.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">outcome</span></p>
<p style="top:723.4pt;left:148.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Briyal et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">19</span></p>
<p style="top:667.1pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2012 Rat</span></p>
<p style="top:588.7pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BQ123</span></p>
<p style="top:416.0pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pMCAO</span></p>
<p style="top:354.6pt;left:149.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BD &#x2013; 7 days</span></p>
<p style="top:220.7pt;left:149.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> motor deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative</span></p>
<p style="top:211.7pt;left:158.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">stress parameters (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD) NP</span></p>
<p style="top:211.7pt;left:167.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">via</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress and independent of</span></p>
<p style="top:211.7pt;left:176.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">endothelin receptor.</span></p>
<p style="top:723.4pt;left:184.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Briyal et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">29</span></p>
<p style="top:667.1pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2014 Rat</span></p>
<p style="top:622.4pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.4pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">s.c.</span></p>
<p style="top:507.1pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Non-diabetic, insulin</span></p>
<p style="top:416.0pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pMCAO</span></p>
<p style="top:354.6pt;left:185.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 14 days</span></p>
<p style="top:220.7pt;left:185.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> motor deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative</span></p>
<p style="top:211.7pt;left:194.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">stress parameters (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span></p>
<p style="top:211.7pt;left:203.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax). NP in both non-</span></p>
<p style="top:211.7pt;left:212.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">diabetic &amp; DM models with similar infarct</span></p>
<p style="top:211.7pt;left:221.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">volume reduction, insulin treatment did not</span></p>
<p style="top:211.7pt;left:230.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">reduce infarct volume.</span></p>
<p style="top:723.4pt;left:238.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Chien et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">44</span></p>
<p style="top:667.1pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2015 Rat</span></p>
<p style="top:622.4pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">PEx-4</span></p>
<p style="top:531.4pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">s.c.</span></p>
<p style="top:507.1pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Non-diabetic, Ex-4</span></p>
<p style="top:416.0pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l tCCAO (10)</span></p>
<p style="top:407.1pt;left:248.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">&amp; hypotension</span></p>
<p style="top:354.6pt;left:239.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 14 days</span></p>
<p style="top:220.7pt;left:239.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> brain oedema,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cognitive deficit,</span></p>
<p style="top:211.7pt;left:248.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral blood flow. PEx-4</span></p>
<p style="top:211.7pt;left:257.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">more NP than Ex-4 in DM.</span></p>
<p style="top:723.4pt;left:265.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zhang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">45</span></p>
<p style="top:667.1pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2015 Mouse</span></p>
<p style="top:588.7pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Pro-GLP-1</span></p>
<p style="top:531.4pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">shRNA</span></p>
<p style="top:416.0pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:354.6pt;left:266.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 7 days</span></p>
<p style="top:220.7pt;left:266.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:275.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax). NP not glucose</span></p>
<p style="top:211.7pt;left:284.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">dependent. NP blocked by shRNA (suggesting</span></p>
<p style="top:211.7pt;left:293.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">GLP-1R mediated NP)</span></p>
<p style="top:723.4pt;left:301.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Jiang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">38</span></p>
<p style="top:667.1pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Rat</span></p>
<p style="top:622.4pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">rhGLP-1</span></p>
<p style="top:531.4pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">nimodipine, insulin</span></p>
<p style="top:416.0pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:354.6pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">TDS &#x2013; 14 days</span></p>
<p style="top:220.7pt;left:302.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP in DM&#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume (more than insulin</span></p>
<p style="top:211.7pt;left:311.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">group),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> brain injury</span></p>
<p style="top:211.7pt;left:320.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">markers (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> S100B,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> NSE,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MBP)</span></p>
<p style="top:723.4pt;left:328.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zhang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">46</span></p>
<p style="top:667.1pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Mouse</span></p>
<p style="top:588.7pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DMB</span></p>
<p style="top:531.4pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">p.o.</span></p>
<p style="top:507.1pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4, Ex-9-39, shRNA</span></p>
<p style="top:416.0pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:354.6pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">30</span></p>
<p style="top:220.7pt;left:329.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP given orally&#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological</span></p>
<p style="top:211.7pt;left:338.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax). No impact</span></p>
<p style="top:211.7pt;left:347.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">on plasma insulin and glucose levels in non-</span></p>
<p style="top:211.7pt;left:356.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">diabetic mice. DMB activation of GLP-1R dif-</span></p>
<p style="top:211.7pt;left:365.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">ferent to Ex-4. NP blocked by shRNA but not</span></p>
<p style="top:211.7pt;left:374.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">by Ex-9-39.</span></p>
<p style="top:723.4pt;left:382.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zhang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">22</span></p>
<p style="top:667.1pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Mouse</span></p>
<p style="top:588.7pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.n.</span></p>
<p style="top:507.1pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Intraperitoneal Ex-4, shRNA</span></p>
<p style="top:416.0pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:354.6pt;left:383.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 7 days</span></p>
<p style="top:220.7pt;left:383.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP given intranasally &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span></p>
<p style="top:211.7pt;left:392.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3)</span></p>
<p style="top:209.4pt;left:401.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Intranasal route produced</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> CNS concentra-</span></p>
<p style="top:211.7pt;left:410.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">tion than intraperitoneal No impact on plasma</span></p>
<p style="top:211.7pt;left:419.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">insulin and glucose levels and NP was blocked</span></p>
<p style="top:211.7pt;left:428.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">by shRNA suggesting NP is GLP-1R mediated.</span></p>
<p style="top:723.4pt;left:436.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Kim et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">23</span></p>
<p style="top:667.1pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2017 Rat</span></p>
<p style="top:588.7pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.c.v</span></p>
<p style="top:507.1pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-9-39</span></p>
<p style="top:416.0pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. MCAO (60)</span></p>
<p style="top:354.6pt;left:437.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">30</span></p>
<p style="top:220.7pt;left:437.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume (by up to 75%),</span></p>
<p style="top:211.7pt;left:446.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative damage/</span></p>
<p style="top:211.7pt;left:455.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">inflammation (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> COX-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> PE2)</span></p>
<p style="top:723.4pt;left:463.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Li et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">48</span></p>
<p style="top:667.1pt;left:464.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2017 Rat</span></p>
<p style="top:588.7pt;left:464.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OXM</span></p>
<p style="top:531.4pt;left:464.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.c.v.</span></p>
<p style="top:416.0pt;left:464.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:354.6pt;left:464.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">15</span></p>
<p style="top:220.7pt;left:464.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> locomotive activity</span></p>
<p style="top:723.4pt;left:470.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Abdel-latif et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">42</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> 2018 Rat</span></p>
<p style="top:622.4pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Lixisenatide</span></p>
<p style="top:531.4pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">glimepiride</span></p>
<p style="top:416.0pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l. tCCAO (30)</span></p>
<p style="top:354.6pt;left:473.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 14 days</span></p>
<p style="top:220.7pt;left:473.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:482.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> catalase),</span></p>
<p style="top:211.7pt;left:491.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation/apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TNF-</span></p>
<p style="top:211.7pt;left:500.4pt;line-height:7.0pt"><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">a</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">). Lixisenatide more NP than glimepiride.</span></p>
<p style="top:723.4pt;left:508.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Fang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">39</span></p>
<p style="top:667.1pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2018 Rat</span></p>
<p style="top:622.4pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">rhGLP-1</span></p>
<p style="top:531.4pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">nimodipine</span></p>
<p style="top:416.0pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:354.6pt;left:509.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">TDS &#x2013; 14 days</span></p>
<p style="top:220.7pt;left:509.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:518.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress parameters (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span></p>
<p style="top:211.7pt;left:527.6pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-</span></p>
<p style="top:211.7pt;left:536.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">3),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">EAAT2,</span></p>
<p style="top:109.2pt;left:551.9pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">(continued)</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">17</span></p>


<p style="top:721.8pt;left:49.3pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 1.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Continued.</span></p>
<p style="top:723.4pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Author</span></p>
<p style="top:667.2pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Year</span></p>
<p style="top:647.6pt;left:83.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Animal</span></p>
<p style="top:647.6pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">model</span></p>
<p style="top:622.4pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Co-morb.</span></p>
<p style="top:588.7pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Drug</span></p>
<p style="top:531.5pt;left:83.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Admin</span></p>
<p style="top:531.5pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">route</span></p>
<p style="top:507.2pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Sub-studies</span></p>
<p style="top:416.1pt;left:74.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Stroke</span></p>
<p style="top:416.1pt;left:83.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">induction</span></p>
<p style="top:416.1pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(time/min)</span></p>
<p style="top:354.6pt;left:66.1pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Administration time (min)</span></p>
<p style="top:354.6pt;left:83.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Pre-</span></p>
<p style="top:354.6pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:306.8pt;left:83.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Post-</span></p>
<p style="top:306.8pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:220.8pt;left:92.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Main outcomes (NP &#x2013; Neuroprotective)</span></p>
<p style="top:723.4pt;left:107.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Filchenko et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">31</span></p>
<p style="top:667.2pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2018 Rat</span></p>
<p style="top:622.4pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.5pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">s.c.</span></p>
<p style="top:507.2pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Non-diabetic, metformin</span></p>
<p style="top:416.1pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (30)</span></p>
<p style="top:354.6pt;left:109.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 7 days</span></p>
<p style="top:220.8pt;left:109.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit only in</span></p>
<p style="top:211.8pt;left:118.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">non-DM model, NP not associated with gly-</span></p>
<p style="top:211.8pt;left:127.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">cemic control amelioration (Metformin not NP)</span></p>
<p style="top:723.4pt;left:134.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Gad et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">51</span></p>
<p style="top:667.2pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2020 Rat</span></p>
<p style="top:588.7pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Lixisenatide</span></p>
<p style="top:531.5pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.2pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0.7 and 7 nmol/kg lixisenatide</span></p>
<p style="top:416.1pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l. tCCAO (60)</span></p>
<p style="top:354.6pt;left:136.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD &#x2013; 14 days</span></p>
<p style="top:220.8pt;left:135.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress parameters (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span></p>
<p style="top:211.8pt;left:145.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax,</span></p>
<p style="top:211.8pt;left:154.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammatory markers (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MPO,</span></p>
<p style="top:211.8pt;left:162.8pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> IL-1</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">b</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">a</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> viable hippocampal neu-</span></p>
<p style="top:211.8pt;left:172.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">rons on histological staining.</span></p>
<p style="top:123.5pt;left:172.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Higher dose</span></p>
<p style="top:211.8pt;left:181.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Lixisenatide</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> NP</span></p>
<p style="top:723.4pt;left:190.3pt;line-height:7.0pt"><span style="font-family:AdvP7D12,serif;font-size:7.0pt">GLP-1RA administered prior to and following stroke onset</span></p>
<p style="top:723.4pt;left:197.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Hyun Lee et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">17</span></p>
<p style="top:667.2pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2011 Gerbil</span></p>
<p style="top:588.7pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.5pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:416.1pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l. tCCAO (5)</span></p>
<p style="top:354.6pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">120</span></p>
<p style="top:306.8pt;left:199.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">60</span></p>
<p style="top:220.8pt;left:199.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GLP-1R immunore-</span></p>
<p style="top:211.8pt;left:207.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">activity,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> microglial activation</span></p>
<p style="top:723.4pt;left:215.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Darsalia et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">20</span></p>
<p style="top:667.2pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2012 Rat</span></p>
<p style="top:622.4pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.5pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.2pt;left:216.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0.1, 2 or 5</span><span style="font-family:AdvPi1,serif;font-size:7.0pt">m</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">g/kg of Ex-4</span></p>
<p style="top:416.1pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:354.6pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BD &#x2013; 4 weeks</span></p>
<p style="top:306.8pt;left:217.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BD &#x2013;2&#x2013;4 weeks</span></p>
<p style="top:220.8pt;left:217.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume (no difference between 2 &amp;</span></p>
<p style="top:211.8pt;left:226.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">4 weeks post MCAO),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> microglial infiltration</span></p>
<p style="top:211.8pt;left:235.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">but marginal effect on activation,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> stem cell</span></p>
<p style="top:211.8pt;left:244.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">proliferation &amp; neuroblast formation.</span></p>
<p style="top:98.7pt;left:244.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP is</span></p>
<p style="top:211.8pt;left:253.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">dose dependent.</span></p>
<p style="top:723.4pt;left:260.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Jia et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">21</span></p>
<p style="top:667.2pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2015 Rat</span></p>
<p style="top:588.7pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4/Catapol</span></p>
<p style="top:531.5pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.c.v.</span></p>
<p style="top:507.2pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-9-39</span></p>
<p style="top:416.1pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:354.6pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">15</span></p>
<p style="top:306.8pt;left:262.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0</span></p>
<p style="top:220.8pt;left:262.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.8pt;left:270.8pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> hippocampal</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">-endorphin expression, NP</span></p>
<p style="top:211.8pt;left:279.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">blocked by Ex-9-39,</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">-endorphin anti-serum</span></p>
<p style="top:211.8pt;left:289.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">and naloxone</span></p>
<p style="top:723.4pt;left:296.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Deng et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">30</span></p>
<p style="top:667.2pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2018 Rat</span></p>
<p style="top:622.4pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.5pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.2pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Non-DM</span></p>
<p style="top:416.1pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pMCAO</span></p>
<p style="top:354.6pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BD &#x2013; 7 days</span></p>
<p style="top:306.8pt;left:298.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">BD &#x2013; 7 days</span></p>
<p style="top:220.8pt;left:298.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP-</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.8pt;left:307.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation</span></p>
<p style="top:211.8pt;left:315.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MPO),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Nrf2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> HO-1 (antioxidative stress</span></p>
<p style="top:211.8pt;left:325.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">signalling pathway) No significant difference in</span></p>
<p style="top:211.8pt;left:334.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP between DM &amp; non-DM</span></p>
<p style="top:723.4pt;left:343.4pt;line-height:7.0pt"><span style="font-family:AdvP7D12,serif;font-size:7.0pt">GLP-1RA administered following stroke onset (including delayed administration)</span></p>
<p style="top:723.4pt;left:350.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Teramoto et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">24</span></p>
<p style="top:667.2pt;left:352.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2011 Mouse</span></p>
<p style="top:588.7pt;left:352.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.5pt;left:352.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">t.v.</span></p>
<p style="top:416.1pt;left:352.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l tMCAO (60)</span></p>
<p style="top:306.8pt;left:352.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0,60,180</span></p>
<p style="top:220.8pt;left:351.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.8pt;left:361.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> microglial</span></p>
<p style="top:211.8pt;left:370.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">activation),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> intracellular cAMP levels (due to</span></p>
<p style="top:211.8pt;left:379.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">GLP-1R activation). NP probably mediated via</span></p>
<p style="top:211.8pt;left:388.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">raised intracellular cAMP levels</span></p>
<p style="top:723.4pt;left:395.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Sato et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">32</span></p>
<p style="top:667.2pt;left:397.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2013 Rat</span></p>
<p style="top:588.7pt;left:397.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.5pt;left:397.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:416.1pt;left:397.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (90)</span></p>
<p style="top:306.8pt;left:397.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">60</span></p>
<p style="top:220.8pt;left:397.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.8pt;left:406.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> VEGF in cortex but not in</span></p>
<p style="top:211.8pt;left:415.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">the striatum.</span></p>
<p style="top:723.4pt;left:422.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Darsalia et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">25</span></p>
<p style="top:667.2pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2014 Mouse</span></p>
<p style="top:622.4pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.5pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.2pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2 month old &amp;</span></p>
<p style="top:498.2pt;left:433.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">14 month obese/DM mice</span></p>
<p style="top:416.1pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (30)</span></p>
<p style="top:306.8pt;left:424.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">90, 180 or 270</span></p>
<p style="top:297.8pt;left:433.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">then OD 1 week</span></p>
<p style="top:220.8pt;left:423.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neuronal survival,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> M2 microglial markers</span></p>
<p style="top:211.8pt;left:433.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Non statistically significant reduction in pro-</span></p>
<p style="top:211.8pt;left:442.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">inflammatory markers. NP in non-DM/DM at</span></p>
<p style="top:211.8pt;left:450.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">50</span><span style="font-family:AdvPi1,serif;font-size:7.0pt">m</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">g/kg at 90/180 min and at 90 min for 5</span><span style="font-family:AdvPi1,serif;font-size:7.0pt">m</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">g/</span></p>
<p style="top:211.8pt;left:460.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">kg. Stroke volume not affected by Ex-4</span></p>
<p style="top:211.8pt;left:469.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">administration. Not NP when Ex-4 adminis-</span></p>
<p style="top:211.8pt;left:478.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">tered 4.5hrs after stroke onset. NP in both</span></p>
<p style="top:211.8pt;left:487.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">young and old animal models</span></p>
<p style="top:723.4pt;left:494.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zhao et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">40</span></p>
<p style="top:667.2pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2015 Rat</span></p>
<p style="top:622.4pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">rhGLP-1</span></p>
<p style="top:531.5pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.2pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">nimodipine</span></p>
<p style="top:416.1pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (120)</span></p>
<p style="top:306.8pt;left:496.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0</span></p>
<p style="top:109.2pt;left:511.2pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">(continued)</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">18</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:721.8pt;left:62.0pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 1.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Continued.</span></p>
<p style="top:723.4pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Author</span></p>
<p style="top:667.1pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Year</span></p>
<p style="top:647.6pt;left:96.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Animal</span></p>
<p style="top:647.6pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">model</span></p>
<p style="top:622.4pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Co-morb.</span></p>
<p style="top:588.7pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Drug</span></p>
<p style="top:531.4pt;left:96.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Admin</span></p>
<p style="top:531.4pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">route</span></p>
<p style="top:507.1pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Sub-studies</span></p>
<p style="top:416.0pt;left:87.1pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Stroke</span></p>
<p style="top:416.0pt;left:96.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">induction</span></p>
<p style="top:416.0pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(time/min)</span></p>
<p style="top:354.6pt;left:78.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Administration time (min)</span></p>
<p style="top:354.6pt;left:96.2pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Pre-</span></p>
<p style="top:354.6pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:306.7pt;left:96.2pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Post-</span></p>
<p style="top:306.7pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:220.7pt;left:105.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Main outcomes (NP &#x2013; Neuroprotective)</span></p>
<p style="top:220.7pt;left:121.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neuronal survival,</span></p>
<p style="top:211.7pt;left:130.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span></p>
<p style="top:211.7pt;left:139.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> nitric oxide damage (iNOS, eNOS)</span></p>
<p style="top:211.7pt;left:149.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Statistically significant reduction in blood glu-</span></p>
<p style="top:211.7pt;left:158.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">cose in high dose group (no hypoglycemia)</span></p>
<p style="top:723.4pt;left:165.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Han et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">47</span></p>
<p style="top:667.1pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Rat</span></p>
<p style="top:588.7pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">GLP-1/GIP (DA)</span></p>
<p style="top:531.4pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">GLP-1RA (SA)</span></p>
<p style="top:416.0pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:306.7pt;left:167.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">60</span></p>
<p style="top:220.7pt;left:166.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:175.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> nitric oxide</span></p>
<p style="top:211.7pt;left:185.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">damage (iNOS). DA more NP than SA.</span></p>
<p style="top:723.4pt;left:192.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Chen et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">26</span></p>
<p style="top:667.1pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Mouse</span></p>
<p style="top:588.7pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Warfarin &amp; Ex-4</span></p>
<p style="top:531.4pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">t.v.</span></p>
<p style="top:507.1pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">P13K inhibitor</span></p>
<p style="top:416.0pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (45)</span></p>
<p style="top:306.7pt;left:194.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0</span></p>
<p style="top:220.7pt;left:193.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> BBB</span></p>
<p style="top:211.7pt;left:202.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">integrity,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> 8-OHdG,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span></p>
<p style="top:211.7pt;left:211.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">HHE),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation, NP blocked by P13K</span></p>
<p style="top:211.7pt;left:221.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">inhibitor. Ameliorated warfarin associated</span></p>
<p style="top:211.7pt;left:230.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">hemorrhagic transformation.</span></p>
<p style="top:723.4pt;left:237.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Kuroki et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">27</span></p>
<p style="top:667.1pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Mouse</span></p>
<p style="top:622.4pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">insulin</span></p>
<p style="top:416.0pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:306.7pt;left:239.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">60</span></p>
<p style="top:220.7pt;left:238.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Hyperglycemia associated with</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span></p>
<p style="top:211.7pt;left:247.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral oedema,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> hemorrhagic transforma-</span></p>
<p style="top:211.7pt;left:256.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">tion. Ex-4 NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral</span></p>
<p style="top:211.7pt;left:265.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">oedema,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation</span></p>
<p style="top:211.7pt;left:274.5pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">a</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MMP-9 activation,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Iba-1 positive</span></p>
<p style="top:211.7pt;left:284.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">microglia, NP in hyperglycemic model. Insulin</span></p>
<p style="top:211.7pt;left:293.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">not NP.</span></p>
<p style="top:723.4pt;left:300.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Li et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">50</span></p>
<p style="top:667.1pt;left:302.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Mouse</span></p>
<p style="top:622.4pt;left:302.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">DM</span></p>
<p style="top:588.7pt;left:302.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4 or liraglutide i.p.</span></p>
<p style="top:416.0pt;left:302.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (60)</span></p>
<p style="top:306.7pt;left:302.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0, 3, 6 or 12hrs</span></p>
<p style="top:220.7pt;left:301.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit including</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> bladder</span></p>
<p style="top:211.7pt;left:310.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">dysfunction,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral microcirculation.</span></p>
<p style="top:211.7pt;left:319.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral oedema,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> DHE,</span></p>
<p style="top:211.7pt;left:328.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> ROS,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> SOD),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3,</span></p>
<p style="top:211.7pt;left:337.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TUNEL,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> PARP,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2),</span></p>
<p style="top:211.7pt;left:346.5pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> ICAM-1, NF-2</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">j</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">B, p50, p65).</span></p>
<p style="top:723.4pt;left:354.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Yang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">28</span></p>
<p style="top:667.1pt;left:356.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Rat</span></p>
<p style="top:588.7pt;left:356.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-4</span></p>
<p style="top:531.4pt;left:356.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">t.v.</span></p>
<p style="top:416.0pt;left:356.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO &amp;</span></p>
<p style="top:407.1pt;left:365.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l. tCCAO (60)</span></p>
<p style="top:306.7pt;left:356.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0 &amp; 24hrs</span></p>
<p style="top:220.7pt;left:355.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> DNA damage (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> APE1,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TUNEL)</span></p>
<p style="top:723.4pt;left:372.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zhu et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">33</span></p>
<p style="top:667.1pt;left:374.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2016 Rat</span></p>
<p style="top:588.7pt;left:374.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.4pt;left:374.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">s.c.</span></p>
<p style="top:416.0pt;left:374.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l pMCAO</span></p>
<p style="top:306.7pt;left:374.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">1hr, then OD for</span></p>
<p style="top:297.7pt;left:383.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">1, 3 and 7 days</span></p>
<p style="top:220.7pt;left:373.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:382.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> ROS,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3, -8, -9,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> PARP,</span></p>
<p style="top:211.7pt;left:391.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> DNA damage (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TUNEL),</span></p>
<p style="top:211.7pt;left:400.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> stress related hyperglycemia without causing</span></p>
<p style="top:211.7pt;left:410.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">hypoglycemia.</span></p>
<p style="top:723.4pt;left:417.6pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Dong et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">34</span></p>
<p style="top:667.1pt;left:419.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2017 Rat</span></p>
<p style="top:588.7pt;left:419.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:531.4pt;left:419.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">s.c.</span></p>
<p style="top:416.0pt;left:419.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. MCAO (90)</span></p>
<p style="top:306.7pt;left:419.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">24hrs, then OD</span></p>
<p style="top:297.7pt;left:428.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">for 4 weeks</span></p>
<p style="top:220.7pt;left:418.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GLP-1R expression,</span></p>
<p style="top:211.7pt;left:427.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> glucose metabolism in ischemic penumbra</span></p>
<p style="top:211.7pt;left:437.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(18-FDG-PET)</span></p>
<p style="top:163.6pt;left:436.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurovascular remodelling</span></p>
<p style="top:211.7pt;left:445.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> NeuN,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GFAP,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> vWF). NP when first dose</span></p>
<p style="top:211.7pt;left:455.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">delayed by 1 day</span></p>
<p style="top:723.4pt;left:460.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Abdel-latif et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">41</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> 2018 Rat</span></p>
<p style="top:588.7pt;left:464.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Lixisenatide</span></p>
<p style="top:531.4pt;left:464.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.1pt;left:464.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-9-39, pentoxyphylline</span></p>
<p style="top:416.0pt;left:464.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">b.l. tCCAO (30)</span></p>
<p style="top:306.7pt;left:464.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">1 &amp; 24hrs</span></p>
<p style="top:220.7pt;left:463.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:211.7pt;left:472.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (caspase-3),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress</span></p>
<p style="top:211.7pt;left:481.7pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSH,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> MDA,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> catalase,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> NO),</span></p>
<p style="top:211.7pt;left:490.5pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation (TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">a</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">) &#x2013; these effects not</span></p>
<p style="top:211.7pt;left:500.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">inhibited by GLP-1R antagonist Ex-39 suggest-</span></p>
<p style="top:211.7pt;left:509.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">ing GLP-1R independent pathway.</span></p>
<p style="top:109.2pt;left:524.0pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">(continued)</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">19</span></p>


<p style="top:722.5pt;left:109.3pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 1.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Continued.</span></p>
<p style="top:724.1pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Author</span></p>
<p style="top:667.8pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Year</span></p>
<p style="top:648.3pt;left:143.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Animal</span></p>
<p style="top:648.3pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">model</span></p>
<p style="top:623.1pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Co-morb.</span></p>
<p style="top:589.4pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Drug</span></p>
<p style="top:532.1pt;left:143.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Admin</span></p>
<p style="top:532.1pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">route</span></p>
<p style="top:507.9pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Sub-studies</span></p>
<p style="top:416.8pt;left:134.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Stroke</span></p>
<p style="top:416.8pt;left:143.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">induction</span></p>
<p style="top:416.8pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(time/min)</span></p>
<p style="top:355.3pt;left:126.1pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Administration time (min)</span></p>
<p style="top:355.3pt;left:143.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Pre-</span></p>
<p style="top:355.3pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:307.4pt;left:143.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">Post-</span></p>
<p style="top:307.4pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D0C,serif;font-size:7.0pt">ischemia</span></p>
<p style="top:221.4pt;left:152.4pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Main outcomes (NP &#x2013; Neuroprotective)</span></p>
<p style="top:724.1pt;left:167.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Chen et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">35</span></p>
<p style="top:667.8pt;left:169.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2018 Mouse</span></p>
<p style="top:589.4pt;left:169.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:532.1pt;left:169.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:416.8pt;left:169.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pMCAO</span></p>
<p style="top:307.4pt;left:168.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">24hrs, then OD for 14 days NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:212.4pt;left:178.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> angiogenesis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">VEGF)</span></p>
<p style="top:137.9pt;left:178.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">No significant differ-</span></p>
<p style="top:212.4pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">ence in blood glucose levels between liraglutide</span></p>
<p style="top:212.4pt;left:196.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">and controls (as expected, stimulated insulin</span></p>
<p style="top:212.4pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">release is in a blood-glucose dependent</span></p>
<p style="top:212.4pt;left:214.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">manner). NP when first dose delayed by 1 day</span></p>
<p style="top:724.1pt;left:221.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Wang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">49</span></p>
<p style="top:667.8pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2018 Mouse</span></p>
<p style="top:589.4pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">P7C3</span></p>
<p style="top:532.1pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">t.v.</span></p>
<p style="top:507.9pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Ex-9-39</span></p>
<p style="top:416.8pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. tMCAO (40)</span></p>
<p style="top:307.4pt;left:223.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">120</span></p>
<p style="top:221.4pt;left:223.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurogenesis</span></p>
<p style="top:212.4pt;left:231.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> doublecortin,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">-tub3,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> adam11,</span></p>
<p style="top:212.4pt;left:240.9pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> adamts20,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> GSK-3)</span></p>
<p style="top:141.8pt;left:241.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP is GLP-1R</span></p>
<p style="top:212.4pt;left:250.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">dependent.</span></p>
<p style="top:724.1pt;left:257.8pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Yang et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">43</span></p>
<p style="top:667.8pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2019 Rat</span></p>
<p style="top:589.4pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Semaglutide</span></p>
<p style="top:532.1pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.9pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Blood glucose monitoring</span></p>
<p style="top:416.8pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pMCAO</span></p>
<p style="top:307.4pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2hrs, then alternate</span></p>
<p style="top:298.4pt;left:268.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">days 1,7,14 or 21 days</span></p>
<p style="top:221.4pt;left:259.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span></p>
<p style="top:212.4pt;left:268.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neuronal loss,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bax,</span></p>
<p style="top:212.4pt;left:276.9pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3),</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurogenesis, improved growth</span></p>
<p style="top:212.4pt;left:286.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">factor signalling (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">&quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> ERK1,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> ERS-1), No hypo-</span></p>
<p style="top:212.4pt;left:295.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">glycemia in normoglycemic model.</span></p>
<p style="top:724.1pt;left:302.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">He et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">36</span></p>
<p style="top:667.8pt;left:304.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2019 Mice</span></p>
<p style="top:589.4pt;left:304.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:532.1pt;left:304.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:416.8pt;left:304.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l. pCCAO</span></p>
<p style="top:307.4pt;left:304.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">OD for 7 days</span></p>
<p style="top:221.4pt;left:304.0pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> neurological deficit,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> oxidative stress</span></p>
<p style="top:724.1pt;left:311.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Zeng et al.</span><span style="font-family:AdvP7D09,serif;font-size:4.9pt">37</span></p>
<p style="top:667.8pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">2020 Rat</span></p>
<p style="top:589.4pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">Liraglutide</span></p>
<p style="top:532.1pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">i.p.</span></p>
<p style="top:507.9pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">P13k inhibitor</span></p>
<p style="top:416.8pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">u.l pMCAO</span></p>
<p style="top:307.4pt;left:313.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">0 then OD</span></p>
<p style="top:221.4pt;left:312.9pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">NP &#x2013;</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> infarct volume,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> cerebral oedema,</span></p>
<p style="top:212.4pt;left:322.0pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> apoptosis (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> &quot;</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> Bcl-2,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> caspase-3,</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt"> #</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TUNEL),</span></p>
<p style="top:212.4pt;left:330.7pt;line-height:7.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> inflammation (</span><span style="font-family:AdvP4C4E74,serif;font-size:7.0pt">#</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt"> TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">a</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">, IL-18, IL-1</span><span style="font-family:AdvPSMP10,serif;font-size:7.0pt">b</span><span style="font-family:AdvP7D09,serif;font-size:7.0pt">, IL-6,</span></p>
<p style="top:212.4pt;left:340.3pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">COX-2) P13k inhibitor partially reversed NP</span></p>
<p style="top:212.4pt;left:349.2pt;line-height:7.0pt"><span style="font-family:AdvP7D09,serif;font-size:7.0pt">effects.</span></p>
<p style="top:723.3pt;left:365.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">SA: single agonist; DA: dual agonist; Ex-4- exendin-4; PEx-4: Exendin-4 loaded poly-microspheres; Ex-9-39: GLP-1R antagonist; pro-GLP-1: long acting GLP-1RA; rhGLP-1: recombinant human GLP-1; DMB:</span></p>
<p style="top:723.3pt;left:375.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">6,7-dichloro-2-methyl-sulfonyl-3-N-tert-butylaminoquinoxaline; OXM: oxyntomodulin; shRNA: small hairpin RNA (targets GLP-1R); BQ123- endothelin receptor antagonist; P7C3- aminopropyl carbazole</span></p>
<p style="top:723.3pt;left:385.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">compound; i.p.: intraperitoneal; s.c.: subcutaneous; p.o.: oral; i.n.: intranasal; t.v.: transvenous; i.c.v.: intracerebroventricular; OD/BD/TDS: once/twice/three times daily; DM: diabetes mellitus; Non-DM: non</span></p>
<p style="top:723.3pt;left:395.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">diabetes mellitus (healthy); u.l.: unilateral; b.l.: bilateral; MCAO: middle cerebral artery occlusion; CCAO: common carotid artery occlusion; (t/p)MCAO: transient/permanent; SOD: superoxide dismutase;</span></p>
<p style="top:723.3pt;left:405.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">MDA: malondialdehyde; GSH: glutathione; 8-OHdG: 8-hydroxy-2-deoxyguanosine; HHE: 4-hydroxyhexenal; DHE: dihydroethidium; ROS: reactive oxygen species; Bcl-2: B cell lymphoma 2; Bax: Bcl-2-like</span></p>
<p style="top:723.3pt;left:415.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">protein 4; Caspase-3; PARP: poly-ADP ribose polymerase; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; S100b: s100- calcium binding protein B; NSE: neuron specific enolase; MBP:</span></p>
<p style="top:723.3pt;left:425.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">myelin basic protein; COX-2: cyclo-oxygenase-2; PE2: Prostaglandin E2; EAAT2: Excitatory amino acid transporter-2; MPO: myeloperoxidase; HO-1: heme oxygenase-1; Nrf2: nuclear factor erythroid-2;</span></p>
<p style="top:723.3pt;left:435.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">NOS: nitric oxide synthase; BBB: blood brain barrier; MMP-9: matrix metalloproteinase-9; ICAM-1: intracellular adhesion molecule-1; NeuN: neuronal nuclear protein (neuronal marker); GFAP: Glial</span></p>
<p style="top:723.3pt;left:444.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">fibrillary acidic protein (glial marker); vWF: von Willebrand factor (endothelial marker);</span><span style="font-family:AdvPSMP10,serif;font-size:8.0pt"> b</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">-tub3: beta tubulin III; GSK-3: glycogen synthase kinase 3; IL: interleukin.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">20</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:72.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between 14 days prior and 15 minutes prior to stroke</span></p>
<p style="top:84.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onset, for one to three times daily.</span></p>
<p style="top:96.8pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">A further four studies administered GLP-1RAs</span></p>
<p style="top:108.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">prior to and following stroke onset for between 0 and</span></p>
<p style="top:120.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">four weeks &#x2013; with dosing schedules of up to twice</span></p>
<p style="top:132.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">daily.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">17,20,21,30</span></sup></p>
<p style="top:144.8pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Most closely aligned with the proposed clinical</span></p>
<p style="top:156.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">application of administering treatment to GLP-1RA</span></p>
<p style="top:168.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">na&#x131;&#xa8;ve patients in the hyper-acute AIS setting, 17 studies</span></p>
<p style="top:180.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">only administered the medication following stroke</span></p>
<p style="top:192.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onset.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">24&#x2013;28,32&#x2013;37,40,41,43,47,49,50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">First dose was delayed</span></p>
<p style="top:204.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between 0 min and 24 h post-onset and continued for</span></p>
<p style="top:216.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">up to four weeks.</span></p>
<p style="top:228.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Alterations in physiological parameters such as</span></p>
<p style="top:240.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">body temperature have the potential to impact the out-</span></p>
<p style="top:252.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">come of stroke. Li et al. reported no signi&#xfb01;cant change</span></p>
<p style="top:264.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in body temperature when measured before and after</span></p>
<p style="top:276.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment with exendin-4.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">18</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">We did not identify any</span></p>
<p style="top:288.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RA study of AIS which varied temperature</span></p>
<p style="top:300.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between groups. Most studies regulated body temper-</span></p>
<p style="top:312.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ature within normal physiological parameters during</span></p>
<p style="top:324.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MCAO surgery and animals were housed within a</span></p>
<p style="top:336.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">temperature-controlled environment.</span></p>
<p style="top:360.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Quality of included studies.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Pre-clinical study meth-</span></p>
<p style="top:372.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">odology was appraised according to the STAIR 2009</span></p>
<p style="top:384.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">criteria, with a maximum available score of 7. Median</span></p>
<p style="top:396.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">score was 3 (range 2&#x2013;7). Inclusion/exclusion criteria</span></p>
<p style="top:408.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and reporting of potential con&#xfb02;icts of interest/funding</span></p>
<p style="top:420.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were consistently reported in 100% and 94% of studies,</span></p>
<p style="top:432.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">respectively. Fewer studies commented on randomisa-</span></p>
<p style="top:444.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion (54%), allocation concealment (17%) and blinded</span></p>
<p style="top:456.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">assessment of outcome (43%). Only four studies (11%)</span></p>
<p style="top:468.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported performing a sample size calculation.</span></p>
<p style="top:480.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reporting of pre-clinical studies was also assessed</span></p>
<p style="top:492.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">using the ARRIVE guidelines, with a maximum score</span></p>
<p style="top:504.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of 36. Median score was 22 (range 14&#x2013;29). Methods,</span></p>
<p style="top:516.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">statistical analysis, outcomes and con&#xfb01;dence intervals</span></p>
<p style="top:528.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were well reported, as were ethical and funding state-</span></p>
<p style="top:540.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ments, but the justi&#xfb01;cation for animal models, transla-</span></p>
<p style="top:552.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion to human biology, limitations and adverse events</span></p>
<p style="top:564.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were frequently not reported.</span></p>
<p style="top:588.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Impact of hyperglycemia in stroke models.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Twelve</span></p>
<p style="top:600.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies were based on hyperglycemic rodents, with or</span></p>
<p style="top:613.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">without a normoglycemic control group.</span></p>
<p style="top:624.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kuroki et al. demonstrated that hyperglycemia was</span></p>
<p style="top:636.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">associated with an increase in infarct volume, cerebral</span></p>
<p style="top:649.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">edema and hemorrhagic transformation in a mouse</span></p>
<p style="top:660.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">model that underwent transient, unilateral occlusion</span></p>
<p style="top:672.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of the MCAO for 60 min.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">27</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">They reported that intra-</span></p>
<p style="top:685.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">peritoneal administration of exendin-4 60 min after</span></p>
<p style="top:696.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke onset was associated with a reduction in these</span></p>
<p style="top:708.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">parameters</span></p>
<p style="top:708.9pt;left:118.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">which</span></p>
<p style="top:708.9pt;left:152.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was</span></p>
<p style="top:708.9pt;left:176.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not</span></p>
<p style="top:708.9pt;left:199.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">replicated</span></p>
<p style="top:708.9pt;left:250.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by</span></p>
<p style="top:708.9pt;left:269.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">insulin</span></p>
<p style="top:721.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">monotherapy.</span></p>
<p style="top:72.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Briyal et al. reported that liraglutide reduced infarct</span></p>
<p style="top:84.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">volume by a similar amount in both diabetic and nor-</span></p>
<p style="top:96.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">moglyemic models, but this neuroprotection was again</span></p>
<p style="top:108.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not reproduced in the insulin treatment arm despite</span></p>
<p style="top:120.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resolution of hyperglycemia.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Deng et al. further con-</span></p>
<p style="top:132.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;rmed neuroprotection was independent of glycemic</span></p>
<p style="top:144.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">status prior to stroke onset.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">30</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Jiang et al. reported</span></p>
<p style="top:156.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that stroke infarct volume in the rhGLP-1 group was</span></p>
<p style="top:168.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">signi&#xfb01;cantly reduced when compared to insulin treat-</span></p>
<p style="top:180.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">38</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Metformin was also shown to ameliorate</span></p>
<p style="top:192.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hyperglycemia but did not confer the additional neuro-</span></p>
<p style="top:204.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protective outcomes associated with liraglutide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">31</span></sup></p>
<p style="top:216.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">One study demonstrated similar neuroprotective</span></p>
<p style="top:228.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes between 2-month-old healthy mice and 14-</span></p>
<p style="top:240.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">month-old overweight, diabetic mice treated with exen-</span></p>
<p style="top:252.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">din-4.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">25</span></sup></p>
<p style="top:264.9pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Whilst GLP-1RAs were associated with a reduction</span></p>
<p style="top:276.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in blood glucose in hyperglycemic models,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">40</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">no study</span></p>
<p style="top:288.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported hypoglycemia when GLP-1RAs were admin-</span></p>
<p style="top:300.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">istered to normoglycemic models. This is to be expected</span></p>
<p style="top:312.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as GLP-1RA-associated insulin secretion from the pan-</span></p>
<p style="top:324.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">creas is glucose dependent.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">35</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Indeed, Zhang et al. con-</span></p>
<p style="top:336.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cluded</span></p>
<p style="top:336.9pt;left:350.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that</span></p>
<p style="top:336.9pt;left:379.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroprotection</span></p>
<p style="top:336.9pt;left:460.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was</span></p>
<p style="top:336.9pt;left:488.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not</span></p>
<p style="top:336.9pt;left:514.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glucose</span></p>
<p style="top:348.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dependent.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">45</span></sup></p>
<p style="top:360.9pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Yang et al. monitored blood glucose in rats which</span></p>
<p style="top:372.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">underwent intraperitoneal administration of semaglu-</span></p>
<p style="top:384.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tide starting 2 h following unilateral permanent MCAO</span></p>
<p style="top:396.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">occlusion, further demonstrating neuroprotection in</span></p>
<p style="top:408.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the absence of hypoglycemic episodes.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup></p>
<p style="top:432.9pt;left:322.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Infarct volume and neuronal survival.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Administration</span></p>
<p style="top:444.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of GLP-1RAs prior to, at the point of, or delayed fol-</span></p>
<p style="top:456.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lowing stroke onset were associated with reduction in</span></p>
<p style="top:468.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">infarct volume. In total, nine studies demonstrated a</span></p>
<p style="top:480.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction in infarct volume with exendin-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">18&#x2013;24,26,27</span></sup></p>
<p style="top:492.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eight with liraglutide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29&#x2013;33,35&#x2013;37</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">three with rhGLP-1,</span></p>
<p style="top:504.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">three with lixisenatide and one with each of PEx-4,</span></p>
<p style="top:516.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proGLP-1, DMB, OXM, GLP-1/GIP DA and sema-</span></p>
<p style="top:528.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glutide. Liraglutide was associated with a reduction in</span></p>
<p style="top:540.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">infarct volume when the &#xfb01;rst dose was delayed by up to</span></p>
<p style="top:552.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1 day.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">35</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kim et al. reported a reduction in infarct</span></p>
<p style="top:564.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">volume by up to 75% in a rat model of transient</span></p>
<p style="top:576.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MCAO. Darsalia et al. reported that exendin-4 admin-</span></p>
<p style="top:588.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">istration was associated with a reduction in stroke</span></p>
<p style="top:600.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">volume when administered for four weeks prior to,</span></p>
<p style="top:612.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:612.9pt;left:334.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">two</span></p>
<p style="top:612.9pt;left:359.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to</span></p>
<p style="top:612.9pt;left:376.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">four weeks</span></p>
<p style="top:612.9pt;left:429.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">following</span></p>
<p style="top:612.9pt;left:478.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke</span></p>
<p style="top:612.9pt;left:512.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onset.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">20</span></sup></p>
<p style="top:624.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">However, in a later study, whereby they only adminis-</span></p>
<p style="top:636.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tered exendin-4 following stroke onset, it did not sig-</span></p>
<p style="top:649.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ni&#xfb01;cantly reduce infarct volume but did reduce overall</span></p>
<p style="top:660.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuronal loss.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">25</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reduction in neuronal loss was also</span></p>
<p style="top:672.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported</span></p>
<p style="top:672.9pt;left:361.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with</span></p>
<p style="top:672.9pt;left:394.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">semaglutide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup></p>
<p style="top:672.9pt;left:469.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rhGLP-1</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">40</span></sup></p>
<p style="top:672.9pt;left:529.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:685.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lixisenatide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">51</span></sup></p>
<p style="top:708.9pt;left:322.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Cellular function.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Apoptosis represents a chain of</span></p>
<p style="top:721.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">enzymatic</span></p>
<p style="top:721.0pt;left:363.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">events</span></p>
<p style="top:721.0pt;left:400.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resulting</span></p>
<p style="top:721.0pt;left:447.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:721.0pt;left:466.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">programmed</span></p>
<p style="top:721.0pt;left:531.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">21</span></p>


<p style="top:72.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">death.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">52</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Whilst controlled apoptosis is essential for the</span></p>
<p style="top:84.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">maintenance of homeostasis, dysregulated apoptosis,</span></p>
<p style="top:96.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for example in within the ischemic penumbra, can</span></p>
<p style="top:108.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">result in increased cell death.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">53</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bcl-2 is an anti-</span></p>
<p style="top:120.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">apoptotic protein which functions at least in part by</span></p>
<p style="top:132.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reducing cytochrome C release from the mitochondria.</span></p>
<p style="top:144.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Conversely,</span></p>
<p style="top:144.8pt;left:108.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bax</span></p>
<p style="top:144.8pt;left:133.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is</span></p>
<p style="top:144.8pt;left:148.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a</span></p>
<p style="top:144.8pt;left:161.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pro-apoptotic</span></p>
<p style="top:144.8pt;left:229.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protein</span></p>
<p style="top:144.8pt;left:268.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:156.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increases cytochrome C levels.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">52</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Increased Bcl-2 and</span></p>
<p style="top:168.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced Bax levels, contributing to an increased</span></p>
<p style="top:180.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bcl-2:Bax ratio and representing reduced levels of apo-</span></p>
<p style="top:192.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ptosis, have been reported in three studies of liraglu-</span></p>
<p style="top:204.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29,33,37</span></sup></p>
<p style="top:204.9pt;left:100.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:204.9pt;left:124.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">one</span></p>
<p style="top:204.9pt;left:147.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study</span></p>
<p style="top:204.9pt;left:179.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for</span></p>
<p style="top:204.9pt;left:199.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">each</span></p>
<p style="top:204.9pt;left:227.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pro-GLP-1,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">45</span></sup></p>
<p style="top:216.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rhGLP-1,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">39</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">DMB,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">22</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">exendin-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">lixisenatide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">51</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-</span></p>
<p style="top:228.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1/GIP DA</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">47</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and semaglutide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Critically, this reduc-</span></p>
<p style="top:240.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion of apoptosis was reproduced in normoglycemic</span></p>
<p style="top:252.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models when administered after stroke onset.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">33,37,43,47</span></sup></p>
<p style="top:264.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Caspase</span></p>
<p style="top:264.9pt;left:106.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proteins</span></p>
<p style="top:264.9pt;left:150.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are</span></p>
<p style="top:264.9pt;left:173.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">also</span></p>
<p style="top:264.9pt;left:200.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pro-apoptotic</span></p>
<p style="top:264.9pt;left:268.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:276.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased levels are associated with higher rates of</span></p>
<p style="top:288.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell</span></p>
<p style="top:288.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">death.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">54</span></sup></p>
<p style="top:288.9pt;left:118.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Liraglutide,</span></p>
<p style="top:288.9pt;left:179.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exendin-4,</span></p>
<p style="top:288.9pt;left:234.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lixisenatide,</span></p>
<p style="top:300.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rhGLP-1 and semaglutide have been shown to reduce</span></p>
<p style="top:312.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">levels</span></p>
<p style="top:312.9pt;left:84.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:312.9pt;left:104.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">caspase-3</span></p>
<p style="top:312.9pt;left:156.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:312.9pt;left:175.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pre-clinical</span></p>
<p style="top:312.9pt;left:234.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models</span></p>
<p style="top:312.9pt;left:276.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:324.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">33,37,39,41&#x2013;43,46,50,51</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Zhu et al. have also demon-</span></p>
<p style="top:336.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strated reduced levels of caspase 8 and 9 in models</span></p>
<p style="top:348.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administered liraglutide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">33</span></sup></p>
<p style="top:360.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cleavage of PARP by caspases is a signal of apo-</span></p>
<p style="top:372.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ptosis and has been implicated in cerebral ischemia.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">53</span></sup></p>
<p style="top:384.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reduction in PARP has been demonstrated with both</span></p>
<p style="top:396.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">liraglutide and exendin-4 treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">33,50</span></sup></p>
<p style="top:408.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">TUNEL assays detect DNA degradation during the</span></p>
<p style="top:420.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">later stages of apoptosis and have demonstrated</span></p>
<p style="top:432.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced apoptotic activity with liraglutide and exen-</span></p>
<p style="top:444.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">din-4.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">37,50,55</span></sup></p>
<p style="top:456.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RA administration following stroke induc-</span></p>
<p style="top:468.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion has been associated with an anti-in&#xfb02;ammatory</span></p>
<p style="top:480.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effect.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">26</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Tumor necrosis factor alpha (TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:10.0pt">a</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">) is a cyto-</span></p>
<p style="top:492.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">kine synthesised by many cell lines, but particularly by</span></p>
<p style="top:504.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">macrophages and microglia.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">56</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:10.0pt">a</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> is involved with</span></p>
<p style="top:516.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the in&#xfb02;ammatory response following stroke onset.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">56</span></sup></p>
<p style="top:528.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Five studies reported a reduction in TNF-</span><span style="font-family:AdvPSMP10,serif;font-size:10.0pt">a</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> when com-</span></p>
<p style="top:540.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pared to controls, three with lixisenatide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">41,42,51</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and one</span></p>
<p style="top:552.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with each of liraglutide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">37</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and exendin-4.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">27</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Indeed, two</span></p>
<p style="top:564.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:564.9pt;left:87.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported</span></p>
<p style="top:564.9pt;left:132.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced</span></p>
<p style="top:564.9pt;left:174.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">microglial</span></p>
<p style="top:564.9pt;left:225.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">activation</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">17,24</span></sup></p>
<p style="top:576.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">whilst a further study by Darsalia et al. reported</span></p>
<p style="top:588.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduced microglial in&#xfb01;ltration, but a marginal effect</span></p>
<p style="top:600.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on activation.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">20</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reduced levels of other markers of</span></p>
<p style="top:612.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in&#xfb02;ammation, such as myeloperoxidase and interleu-</span></p>
<p style="top:624.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">kin, have also been reported.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">30,37,51</span></sup></p>
<p style="top:636.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">One study reported a non-statistically signi&#xfb01;cant</span></p>
<p style="top:649.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction in pro-in&#xfb02;ammatory markers.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">25</span></sup></p>
<p style="top:660.9pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">There is also deterioration in markers of oxidative</span></p>
<p style="top:672.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stress following AIS. Twelve studies reported an</span></p>
<p style="top:685.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement in oxidative stress parameters following</span></p>
<p style="top:696.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RA administration in AIS &#x2013; &#xfb01;ve studies of exen-</span></p>
<p style="top:708.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">din-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">19,24,26,27,50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">four studies of liraglutide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29,30,32,36</span></sup></p>
<p style="top:721.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">two</span></p>
<p style="top:721.0pt;left:76.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:721.0pt;left:96.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lixisenatide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">41,42</span></sup></p>
<p style="top:721.0pt;left:171.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:721.0pt;left:198.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">one</span></p>
<p style="top:721.0pt;left:224.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:721.0pt;left:244.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rhGLP.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">40</span></sup></p>
<p style="top:72.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Predominantly, studies reported reduced levels of</span></p>
<p style="top:84.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">malondialdehyde and increased concentrations of glu-</span></p>
<p style="top:96.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tathione and superoxide dismutase.</span></p>
<p style="top:108.8pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dong et al. performed 18-FDG PET imaging in a</span></p>
<p style="top:120.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rat model of unilateral transient MCAO. In the ani-</span></p>
<p style="top:132.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mals treated with subcutaneous liraglutide, there was</span></p>
<p style="top:144.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">radiological evidence of increased glucose metabolism</span></p>
<p style="top:156.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">within the ischemic penumbra.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">34</span></sup></p>
<p style="top:180.8pt;left:309.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Neurovascular</span></p>
<p style="top:180.8pt;left:378.9pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">function.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> The</span></p>
<p style="top:180.8pt;left:445.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurovascular</span></p>
<p style="top:180.8pt;left:515.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">unit</span></p>
<p style="top:192.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">incorporates both cellular and extracellular compo-</span></p>
<p style="top:204.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nents involved in the regulation of cerebral blood</span></p>
<p style="top:216.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb02;ow and blood-brain barrier function &#x2013; it is involved</span></p>
<p style="top:228.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with the maintenance of cerebral homeostasis and con-</span></p>
<p style="top:240.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trol of cerebral blood &#xfb02;ow.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">57</span></sup></p>
<p style="top:252.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RAs have been shown to increase cerebral</span></p>
<p style="top:264.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blood &#xfb02;ow following AIS when compared with con-</span></p>
<p style="top:276.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trols.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">44</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Li et al. reported that cerebral microcirculation</span></p>
<p style="top:288.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is reduced following AIS, but improved to a similar</span></p>
<p style="top:300.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">degree within 4&#x2013;12 h after MCAO in diabetic mice</span></p>
<p style="top:312.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treated with either liraglutide or exendin-4 after stroke</span></p>
<p style="top:324.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">induction.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Blood&#x2013;brain barrier integrity has also been</span></p>
<p style="top:336.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">shown to improve with GLP-1RA treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">26</span></sup></p>
<p style="top:348.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Vascular</span></p>
<p style="top:348.9pt;left:355.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">endothelial</span></p>
<p style="top:348.9pt;left:410.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">growth</span></p>
<p style="top:348.9pt;left:449.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">factor</span></p>
<p style="top:348.9pt;left:482.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(VEGF)</span></p>
<p style="top:360.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">known to promote angiogenesis and protect ischemic</span><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">is</span></sup></p>
<p style="top:372.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurons from injury, demonstrating a crucial role in the</span></p>
<p style="top:384.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurovascular remodelling post-AIS.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">58</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Chen et al.</span></p>
<p style="top:396.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated that intraperitoneal liraglutide therapy,</span></p>
<p style="top:408.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administered 24 h following stroke induction and</span></p>
<p style="top:420.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">once daily for 14 days, was associated with increased</span></p>
<p style="top:432.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">VEGF expression when compared with normal saline</span></p>
<p style="top:444.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment at days 7 and 14 post-AIS in a normoglyce-</span></p>
<p style="top:456.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mic model.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">35</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Similarly, Sato et al. demonstrated</span></p>
<p style="top:468.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">upregulation of VEGF in the cerebral cortex of</span></p>
<p style="top:480.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">liraglutide-treated, normoglycemic rats; however, this</span></p>
<p style="top:492.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was not seen within the striatum.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">32</span></sup></p>
<p style="top:504.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Markers of neuronal, glial and endothelial function</span></p>
<p style="top:516.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(NeuN, GFAP and vWF respectively) were used by</span></p>
<p style="top:528.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dong et al. to investigate for evidence of neurovascular</span></p>
<p style="top:540.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">remodelling following AIS. They reported that liraglu-</span></p>
<p style="top:552.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tide, administered to normoglycemic mice at 1 and 24 h</span></p>
<p style="top:564.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">following bilateral, transient CCAO, was associated</span></p>
<p style="top:576.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with signi&#xfb01;cantly higher levels of each marker &#x2013; indi-</span></p>
<p style="top:588.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cating increased remodelling associated with GLP-</span></p>
<p style="top:600.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1RAs following AIS.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">34</span></sup></p>
<p style="top:613.0pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Jiang et al. reported that levels of brain injury</span></p>
<p style="top:624.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">markers (S100B, NSE and MBP) were reduced with</span></p>
<p style="top:636.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">both rhGLP-1 and nimodipine treatments.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">38</span></sup></p>
<p style="top:649.0pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Wang et al. investigated for evidence of increased</span></p>
<p style="top:660.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurogenesis</span></p>
<p style="top:660.9pt;left:361.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">associated</span></p>
<p style="top:660.9pt;left:413.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with</span></p>
<p style="top:660.9pt;left:441.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1R</span></p>
<p style="top:660.9pt;left:487.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">activation.</span></p>
<p style="top:672.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">They reported that doublecortin (marker of newborn</span></p>
<p style="top:685.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroblasts) and</span><span style="font-family:AdvPSMP10,serif;font-size:10.0pt"> b</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">-tubulin III (marker of neurogenesis</span></p>
<p style="top:696.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and neural progenitor activity) levels were signi&#xfb01;cantly</span></p>
<p style="top:708.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">upregulated with P7C3 treatment when compared to</span></p>
<p style="top:721.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">controls. They also reported increased levels of cell</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">22</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:72.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proliferation markers (ki67, BrdU) and neurodevelop-</span></p>
<p style="top:85.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mental markers (adam11, adamts20) alongside markers</span></p>
<p style="top:97.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of increased neurogenesis (GSK-3 inhibition).</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">49</span></sup></p>
<p style="top:109.5pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Darsalia et al. also counted ki67 expressing cells to</span></p>
<p style="top:121.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evaluate stem cell proliferation and reported a two-fold</span></p>
<p style="top:134.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">greater number of proliferating cells in the exendin-4</span></p>
<p style="top:146.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment group compared with controls at two weeks</span></p>
<p style="top:158.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">following stroke induction; however, there was no</span></p>
<p style="top:171.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">detectable</span></p>
<p style="top:171.0pt;left:114.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">difference</span></p>
<p style="top:171.0pt;left:165.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">at</span></p>
<p style="top:171.0pt;left:183.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">four weeks.</span></p>
<p style="top:171.0pt;left:240.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Doublecortin</span></p>
<p style="top:183.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">levels</span></p>
<p style="top:183.4pt;left:94.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:183.4pt;left:123.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">also</span></p>
<p style="top:183.4pt;left:149.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased</span></p>
<p style="top:183.4pt;left:197.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">at</span></p>
<p style="top:183.4pt;left:215.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">two weeks</span></p>
<p style="top:183.4pt;left:267.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:183.4pt;left:284.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:195.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exendin-4 treatment group, with no difference from</span></p>
<p style="top:208.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">controls at four weeks. When using Neun and BrdU</span></p>
<p style="top:220.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">expressing neurons to identify new, mature neurons</span></p>
<p style="top:232.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">generated after stroke onset, there was no difference</span></p>
<p style="top:245.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between the treatment and control groups.</span></p>
<p style="top:256.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Doublecortin levels were also shown to be increased</span></p>
<p style="top:269.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with semaglutide treatment.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup></p>
<p style="top:293.3pt;left:74.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Neurological outcomes.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Assessment of neurological</span></p>
<p style="top:305.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes was heterogeneous amongst studies, with</span></p>
<p style="top:317.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">many utilising a range of different techniques or mod-</span></p>
<p style="top:330.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">i&#xfb01;ed adaptions. Overall, selected neurological assess-</span></p>
<p style="top:342.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ments</span></p>
<p style="top:342.5pt;left:97.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">examined</span></p>
<p style="top:342.5pt;left:147.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">both</span></p>
<p style="top:342.5pt;left:176.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cognitive</span></p>
<p style="top:342.5pt;left:224.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:342.5pt;left:250.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">locomotive</span></p>
<p style="top:354.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurological function.</span></p>
<p style="top:366.9pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Eight</span></p>
<p style="top:366.9pt;left:107.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:366.9pt;left:146.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported</span></p>
<p style="top:366.9pt;left:192.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a</span></p>
<p style="top:366.9pt;left:207.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction</span></p>
<p style="top:366.9pt;left:258.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:366.9pt;left:276.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">post-</span></p>
<p style="top:379.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke neurological de&#xfb01;cit when treated with liraglu-</span></p>
<p style="top:391.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tide,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">29,31&#x2013;36,50</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">six with exendin-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">17&#x2013;19,22,23,26</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">two with</span></p>
<p style="top:403.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rhGLP-1,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">38,39</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">two with lixisenatide</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">41,42</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and one study</span></p>
<p style="top:416.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for each of PEx-4,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">44</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">proGLP-1,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">45</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">DMB,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">46</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">OXM,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">50</span></sup></p>
<p style="top:428.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1/GIP DA,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">47</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">P7C3</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">49</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and semaglutide.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">43</span></sup></p>
<p style="top:72.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nine studies reported a reduction in neurological</span></p>
<p style="top:85.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">de&#xfb01;cit when GLP-1RAs were administered to normo-</span></p>
<p style="top:97.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glycemic models at least 1 h after induction of AIS.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">32&#x2013;</span></sup></p>
<p style="top:107.7pt;left:310.4pt;line-height:7.1pt"><span style="font-family:Times New Roman,serif;font-size:7.1pt">36,41,43,47,49</span></p>
<p style="top:121.8pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Notably, Filchenko et al. reported that whilst reduc-</span></p>
<p style="top:134.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion in neurological de&#xfb01;cit was observed in the non-</span></p>
<p style="top:146.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">diabetic rat model treated with liraglutide, this trend</span></p>
<p style="top:158.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was not observed in the diabetic groups.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">31</span></sup></p>
<p style="top:182.7pt;left:322.4pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Potential mechanisms.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> GLP-1RAs stimulate insulin</span></p>
<p style="top:195.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">secretion from the pancreas in a glucose-dependent</span></p>
<p style="top:207.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">manner. Neuroprotective ef&#xfb01;cacy has been demonstrated</span></p>
<p style="top:219.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in both diabetic and normoglycemic models; their neuro-</span></p>
<p style="top:231.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protection is therefore not glucose-dependent.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">27,31,45</span></sup></p>
<p style="top:243.9pt;left:322.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Whilst it is well documented that GLP-1R levels</span></p>
<p style="top:256.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increase following AIS, the precise mechanism of neu-</span></p>
<p style="top:268.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">roprotection is not completely understood. These have</span></p>
<p style="top:280.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been broadly summarised in Figure 2, re&#xfb02;ecting the</span></p>
<p style="top:293.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">direct and indirect potential mechanisms. To further</span></p>
<p style="top:305.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">understand the role of the GLP-1R, studies have uti-</span></p>
<p style="top:317.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lised targeted GLP-1R shRNA and the GLP-1R antag-</span></p>
<p style="top:330.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onist, Ex-9-39. GLP-1R targeted shRNA has been</span></p>
<p style="top:342.3pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported to block the neuroprotective ef&#xfb01;cacy of</span></p>
<p style="top:354.6pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RAs.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">22,45,46</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">However, whilst there are some</span></p>
<p style="top:366.9pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reports of Ex-3-9 administration blocking neuroprotec-</span></p>
<p style="top:379.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">21</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">suggestive of GLP-1R dependence, other studies</span></p>
<p style="top:391.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">did not demonstrated this trend, highlighting the pos-</span></p>
<p style="top:403.8pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sibility of a GLP-1R independent mechanism.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">41,46</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">For</span></p>
<p style="top:416.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">example, GLP-1</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">[28&#x2013;36]</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">is cleaved from endogenous</span></p>
<p style="top:428.4pt;left:310.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1;</span></p>
<p style="top:428.4pt;left:352.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research</span></p>
<p style="top:428.4pt;left:397.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">has</span></p>
<p style="top:428.4pt;left:421.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">shown</span></p>
<p style="top:428.4pt;left:458.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this</span></p>
<p style="top:428.4pt;left:484.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cell-permeable</span></p>
<img style="position:absolute;transform:matrix(.54848256,0,-0,.547573,43.36667,495.54066)" src="data:image/png;base64,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">
<p style="top:702.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Figure 2.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Proposed neuroprotective mechanism of action for GLP-1RAs in AIS.1. Direct GLP-1R activation by GLP-1RA. 2. Potential</span></p>
<p style="top:712.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">indirect receptor activation by GLP-1RA. 3. GLP-1 sub-units are cell permeable and may affect mitochondrial function, or act on</span></p>
<p style="top:723.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">extra-cellular receptors. 4. GLP-1RAs reduce excitotoxicity.</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">23</span></p>


<p style="top:72.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nonapeptide to have antioxidant, anti-apoptotic and</span></p>
<p style="top:85.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mitochondrial regulatory properties in pancreatic cells</span></p>
<p style="top:97.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#x2013; further research is required to establish its role in</span></p>
<p style="top:109.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neural tissue.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">59</span></sup></p>
<p style="top:121.8pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The reduction in apoptosis, oxidative stress and</span></p>
<p style="top:134.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in&#xfb02;ammation, alongside increased neurogenesis, angio-</span></p>
<p style="top:146.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">genesis and cerebral blood &#xfb02;ow is likely to contribute</span></p>
<p style="top:158.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to the neuroprotective outcomes. Multiple signalling</span></p>
<p style="top:171.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cascades have been studied, with P-Akt/p-eNOS,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">44,50</span></sup></p>
<p style="top:183.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cAMP/PKA</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">22,45,46,49</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and P13k/Akt</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">22,26,33,37,45</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">path-</span></p>
<p style="top:195.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ways implicated in neuroprotection.</span></p>
<p style="top:219.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Clinical studies</span></p>
<p style="top:231.8pt;left:61.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Stroke risk in cardiovascular outcome (safety) trials.</span></p>
<p style="top:244.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">All six licensed GLP-1RAs (Table 2) have reported</span></p>
<p style="top:256.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cardiovascular Outcome Trials (CVOTs). SUSTAIN-</span></p>
<p style="top:268.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6 (semaglutide) and REWIND (dulaglutide) demon-</span></p>
<p style="top:281.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strated a signi&#xfb01;cant reduction in stroke incidence, HR</span></p>
<p style="top:293.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">0.61 (95% CI 0.38&#x2013;0.99,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> p</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xbc;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 0.04) and HR 0.76 (95%</span></p>
<p style="top:305.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">CI 0.61&#x2013;0.94,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> p</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xbc;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 0.017), respectively. LEADER (lira-</span></p>
<p style="top:318.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glutide) reported a non-statistically signi&#xfb01;cant reduc-</span></p>
<p style="top:330.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion in non-fatal stroke incidence, HR 0.89 (95% CI</span></p>
<p style="top:342.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">0.72&#x2013;1.11,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> p</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xbc;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 0.30). This was not reported in ELIXA</span></p>
<p style="top:355.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(lixisenatide),</span></p>
<p style="top:355.1pt;left:117.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EXSCEL</span></p>
<p style="top:355.1pt;left:167.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(exenatide),</span></p>
<p style="top:355.1pt;left:227.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">HARMONY</span></p>
<p style="top:367.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(albiglutide) and notably not in the oral semaglutide</span></p>
<p style="top:379.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study, PIONEER-6.</span></p>
<p style="top:391.8pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Gerstein et al. have recently further analysed the</span></p>
<p style="top:404.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">REWIND trial. They report that participants who</span></p>
<p style="top:416.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">experienced stroke during follow-up were categorised</span></p>
<p style="top:428.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as either ischemic, hemorrhagic, or undetermined and a</span></p>
<p style="top:441.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">modi&#xfb01;ed Rankin scale (mRS) was recorded to assess</span></p>
<p style="top:453.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">severity. Whilst dulaglutide reduced the incidence of</span></p>
<p style="top:465.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ischemic stroke, it did not affect stroke severity.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">60</span></sup></p>
<p style="top:477.7pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Post-hoc analysis of CVOT trial data has identi&#xfb01;ed</span></p>
<p style="top:490.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sub-groups which may potentially derive greater car-</span></p>
<p style="top:502.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">diovascular protection. Mann et al. identi&#xfb01;ed enhanced</span></p>
<p style="top:514.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bene&#xfb01;ts in patients with chronic kidney disease,</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">61</span></sup></p>
<p style="top:72.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">whilst Kang et al. reported increased bene&#xfb01;t in Asian</span></p>
<p style="top:85.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">participants.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">62</span></sup></p>
<p style="top:97.2pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Meta-analysis by Barkas et al.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">63</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated a</span></p>
<p style="top:109.5pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13% reduction in the risk of total stroke associated</span></p>
<p style="top:121.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with GLP-1RA treatment versus placebo (RR 0.87,</span></p>
<p style="top:134.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">95% CI 0.78&#x2013;0.98,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> p</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xbc;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 0.021).</span></p>
<p style="top:158.2pt;left:309.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">GLP-1RAs and stroke in real-world datasets.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> We iden-</span></p>
<p style="top:170.5pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ti&#xfb01;ed eleven published retrospective studies analysing</span></p>
<p style="top:182.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cardiovascular outcomes of T2DM patients who had</span></p>
<p style="top:195.2pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been treated with GLP-1RAs (Table 3). These were</span></p>
<p style="top:207.6pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">conducted using data extracted from insurance/nation-</span></p>
<p style="top:219.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">al databases.</span></p>
<p style="top:231.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Recently, O&#x2019;Brien et al. reported a retrospective</span></p>
<p style="top:244.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cohort study of 132 737 insured adults with T2DM</span></p>
<p style="top:256.6pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">commenced on a second line diabetes medication</span></p>
<p style="top:268.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between 2011 and 2015.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">64</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Adjusting for confounding</span></p>
<p style="top:281.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">variables, GLP-1RAs were associated with a reduction</span></p>
<p style="top:293.6pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in stroke risk (HR 0.65, 95% CI 0.44-0.97) when com-</span></p>
<p style="top:306.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pared to treatment with Dipeptidyl Peptidase-4 (DPP-</span></p>
<p style="top:318.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4) inhibitors. Reduction in stroke risk was reported in a</span></p>
<p style="top:330.6pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">further two studies</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">65,66</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">; however, both Svantstrom</span></p>
<p style="top:343.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">et al. and Anyanwagu et al. did not report this</span></p>
<p style="top:355.3pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trend.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">67,68</span></sup></p>
<p style="top:367.3pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Raparelli et al. reported an increased GLP-1RA</span></p>
<p style="top:379.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">associated reduction in cardiovascular risk in females</span></p>
<p style="top:392.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compared to males.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">69</span></sup></p>
<p style="top:416.0pt;left:309.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">Prospective interventional studies.</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Daly et al. report</span></p>
<p style="top:428.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the &#xfb01;rst pilot, non-randomised interventional study</span></p>
<p style="top:440.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administering exenatide to eleven patients within 12 h</span></p>
<p style="top:453.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of stroke onset followed by twice-daily injections until</span></p>
<p style="top:465.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">discharge.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">70</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">Glucose levels were monitored, followed</span></p>
<p style="top:477.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by a three-month modi&#xfb01;ed Rankin score. Although</span></p>
<p style="top:490.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mild nausea and vomiting were common, they reported</span></p>
<p style="top:502.4pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">no serious adverse events nor associated hypoglycemic</span></p>
<p style="top:514.7pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">episodes. They concluded that exenatide was safe and</span></p>
<p style="top:539.8pt;left:49.6pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 2.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> GLP-1RA characteristics and stroke incidence in CVOTs.</span></p>
<p style="top:557.8pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">ELIXA</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">75</span></sup></p>
<p style="top:557.8pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">LEADER</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">76</span></sup></p>
<p style="top:557.8pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">SUSTAIN-6</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">77</span></sup></p>
<p style="top:557.8pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">EXSCEL</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">78</span></sup></p>
<p style="top:557.8pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">HARMONY</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">79</span></sup></p>
<p style="top:557.8pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">REWIND</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">80</span></sup></p>
<p style="top:557.8pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">PIONEER-6</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">81</span></sup></p>
<p style="top:575.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">GLP-1RA</span></p>
<p style="top:575.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Lixisenatide</span></p>
<p style="top:575.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Liraglutide</span></p>
<p style="top:575.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Semaglutide</span></p>
<p style="top:575.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Exenatide</span></p>
<p style="top:585.4pt;left:316.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">(extended</span></p>
<p style="top:595.4pt;left:316.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">release)</span></p>
<p style="top:575.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Albiglutide</span></p>
<p style="top:575.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Dulaglutide</span></p>
<p style="top:575.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Semaglutide</span></p>
<p style="top:605.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Participants</span></p>
<p style="top:605.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">6 068</span></p>
<p style="top:605.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">9 340</span></p>
<p style="top:605.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">3 297</span></p>
<p style="top:605.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">14 752</span></p>
<p style="top:605.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">9 463</span></p>
<p style="top:605.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">9 901</span></p>
<p style="top:605.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">3 183</span></p>
<p style="top:615.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Median follow-up (years)</span></p>
<p style="top:615.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">2.1</span></p>
<p style="top:615.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">3.8</span></p>
<p style="top:615.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">2.1</span></p>
<p style="top:615.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">3.2</span></p>
<p style="top:615.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">1.6</span></p>
<p style="top:615.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">5.4</span></p>
<p style="top:615.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">1.3</span></p>
<p style="top:625.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Characteristics</span></p>
<p style="top:635.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Administration</span></p>
<p style="top:635.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Subcutaneous Subcutaneous</span></p>
<p style="top:635.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Subcutaneous</span></p>
<p style="top:635.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Subcutaneous</span></p>
<p style="top:635.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Subcutaneous</span></p>
<p style="top:635.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Subcutaneous</span></p>
<p style="top:635.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Oral</span></p>
<p style="top:645.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Dose</span></p>
<p style="top:645.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">10&#x2013;20</span><span style="font-family:AdvPi1,serif;font-size:8.0pt"> m</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">g</span></p>
<p style="top:645.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">1.8 mg</span></p>
<p style="top:645.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">0.5&#x2013;1.0mg</span></p>
<p style="top:645.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">2 mg</span></p>
<p style="top:645.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">30&#x2013;50 mg</span></p>
<p style="top:645.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">1.5 mg</span></p>
<p style="top:645.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">14 mg</span></p>
<p style="top:655.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Frequency</span></p>
<p style="top:655.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-daily</span></p>
<p style="top:655.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-daily</span></p>
<p style="top:655.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-weekly</span></p>
<p style="top:655.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-weekly</span><sup><span style="font-family:AdvP7D09,serif;font-size:5.7pt">a</span></sup></p>
<p style="top:655.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-weekly</span></p>
<p style="top:655.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">once-weekly</span></p>
<p style="top:655.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Once-daily</span></p>
<p style="top:665.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Non-fatal stroke incidence</span></p>
<p style="top:675.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Treatment group &#x2013; no. (%) 54 (1.8)</span></p>
<p style="top:675.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">159 (3.4)</span></p>
<p style="top:675.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">27 (1.6)</span></p>
<p style="top:675.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">169 (2.3)</span></p>
<p style="top:675.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">76 (1.6)</span></p>
<p style="top:675.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">135 (2.7)</span></p>
<p style="top:675.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">12 (0.8)</span></p>
<p style="top:685.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Placebo &#x2013; no. (%)</span></p>
<p style="top:685.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">49 (1.6)</span></p>
<p style="top:685.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">177 (3.8)</span></p>
<p style="top:685.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">44 (2.7)</span></p>
<p style="top:685.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">193 (2.6)</span></p>
<p style="top:685.4pt;left:364.8pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">91 (1.9)</span></p>
<p style="top:685.4pt;left:422.4pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">175 (3.5)</span></p>
<p style="top:685.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">16 (1.0)</span></p>
<p style="top:695.4pt;left:49.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Hazard ratio (95% CI)</span></p>
<p style="top:695.4pt;left:141.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">1.10</span></p>
<p style="top:705.4pt;left:150.6pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">(0.75&#x2013;1.63)</span></p>
<p style="top:695.4pt;left:191.9pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">0.89 (0.72&#x2013;1.11)</span></p>
<p style="top:705.4pt;left:200.9pt;line-height:8.0pt"><span style="font-family:AdvP7D0C,serif;font-size:8.0pt">p</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt"> 0.30</span></p>
<p style="top:695.4pt;left:249.5pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">0.61 (0.38&#x2013;0.99)</span></p>
<p style="top:705.4pt;left:258.5pt;line-height:8.0pt"><span style="font-family:AdvP7D0C,serif;font-size:8.0pt">p</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt"> 0.04</span></p>
<p style="top:695.4pt;left:307.1pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">0.88 (0.72&#x2013;1.08) 0.84 (0.62&#x2013;1.13) 0.76 (0.61&#x2013;0.94)</span></p>
<p style="top:705.4pt;left:431.4pt;line-height:8.0pt"><span style="font-family:AdvP7D0C,serif;font-size:8.0pt">p</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xbc;</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt"> 0.017</span></p>
<p style="top:695.4pt;left:480.0pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">0.74 (0.35&#x2013;1.57)</span></p>
<p style="top:720.9pt;left:49.6pt;line-height:5.7pt"><span style="font-family:AdvP7D09,serif;font-size:5.7pt">a</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Exenatide standard release requires twice-daily administration.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">24</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:721.8pt;left:110.0pt;line-height:9.0pt"><span style="font-family:AdvP7D0F,serif;font-size:9.0pt">Table 3.</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt"> Retrospective database studies.</span></p>
<p style="top:721.8pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Author</span></p>
<p style="top:634.6pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Years studied</span></p>
<p style="top:571.2pt;left:139.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Participants</span></p>
<p style="top:571.2pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">included</span></p>
<p style="top:514.5pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Groups</span></p>
<p style="top:416.0pt;left:139.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Participants on</span></p>
<p style="top:416.0pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA</span></p>
<p style="top:346.8pt;left:128.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA CVD risk</span></p>
<p style="top:346.8pt;left:139.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">(composite) -HR (95% CI)</span></p>
<p style="top:346.8pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">unless otherwise specified</span></p>
<p style="top:215.9pt;left:139.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA Stroke</span></p>
<p style="top:215.9pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Risk -HR(95% CI)</span></p>
<p style="top:131.6pt;left:150.3pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">HR Compared to</span></p>
<p style="top:721.8pt;left:166.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Best et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">82</span></p>
<p style="top:634.6pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2005&#x2013;2009</span></p>
<p style="top:571.2pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">383 525</span></p>
<p style="top:514.5pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide, non-</span></p>
<p style="top:505.5pt;left:179.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">exenatide</span></p>
<p style="top:416.0pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">21 754</span></p>
<p style="top:346.8pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.80 (0.74&#x2013;0.86)</span></p>
<p style="top:215.9pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">NR</span></p>
<p style="top:131.6pt;left:168.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Non-exenatide</span></p>
<p style="top:721.8pt;left:188.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Paul et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">65</span></p>
<p style="top:634.6pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2005&#x2013;2009</span></p>
<p style="top:571.2pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">39 225</span></p>
<p style="top:514.5pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide, exenatide &amp;</span></p>
<p style="top:505.5pt;left:201.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">insulin, insulin</span></p>
<p style="top:416.0pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">10 674</span></p>
<p style="top:346.8pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide 0.50 (0.32&#x2013;0.79)</span></p>
<p style="top:346.8pt;left:201.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide and insulin</span></p>
<p style="top:346.8pt;left:212.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.44 (0.34&#x2013;0.57)</span></p>
<p style="top:215.9pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide</span></p>
<p style="top:215.9pt;left:201.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.50(0.28&#x2013;0.84)</span></p>
<p style="top:215.9pt;left:212.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide &amp; insulin</span></p>
<p style="top:215.9pt;left:223.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.38 (0.27&#x2013;0.54)</span></p>
<p style="top:131.6pt;left:190.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Insulin</span></p>
<p style="top:721.8pt;left:232.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Gejl et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">83</span></p>
<p style="top:634.6pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">1977&#x2013;2011</span></p>
<p style="top:571.2pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">10 073</span></p>
<p style="top:514.5pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Liraglutide, exenatide,</span></p>
<p style="top:505.5pt;left:245.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">insulin, biguianides,</span></p>
<p style="top:505.5pt;left:256.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">glitazones, DPP-4i,</span></p>
<p style="top:505.5pt;left:267.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">SFU</span></p>
<p style="top:416.0pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">1 749</span></p>
<p style="top:346.8pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Liraglutide OR 0.48 (0.38&#x2013;0.62)</span></p>
<p style="top:346.8pt;left:245.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Exenatide OR 1.72 (1.20&#x2013;2.48)</span></p>
<p style="top:215.9pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">NR</span></p>
<p style="top:131.6pt;left:234.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">N/A</span></p>
<p style="top:721.8pt;left:276.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Patorno et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">84</span></p>
<p style="top:634.6pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2005&#x2013;2013</span></p>
<p style="top:571.2pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">219 810</span></p>
<p style="top:514.5pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA, DPP-4i,</span></p>
<p style="top:505.5pt;left:289.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">SFU, insulin</span></p>
<p style="top:416.0pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">29,542</span></p>
<p style="top:346.8pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">i) 1.20 (0.76&#x2013;1.89)</span></p>
<p style="top:346.8pt;left:289.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">ii) 1.05 (0.63&#x2013;1.74)</span></p>
<p style="top:346.8pt;left:300.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">iii) 1.01 (0.73&#x2013;1.41)</span></p>
<p style="top:215.9pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">NR</span></p>
<p style="top:131.6pt;left:278.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">i) DPP-4i</span></p>
<p style="top:131.6pt;left:289.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">ii) SFU</span></p>
<p style="top:131.6pt;left:300.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">iii) insulin</span></p>
<p style="top:721.8pt;left:309.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Ekstr</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:AdvP7D09,serif;font-size:9.0pt">om et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">85</span></p>
<p style="top:634.6pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2005&#x2013;2012</span></p>
<p style="top:571.2pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">20 422</span></p>
<p style="top:514.5pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA, acarbose,</span></p>
<p style="top:505.5pt;left:322.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">insulin, DPP-4i,</span></p>
<p style="top:505.5pt;left:333.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">meglitinide, SU,</span></p>
<p style="top:505.5pt;left:344.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">TZD</span></p>
<p style="top:416.0pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">219</span></p>
<p style="top:346.8pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.26 (0.10&#x2013;0.67)</span></p>
<p style="top:215.9pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">NR</span></p>
<p style="top:131.6pt;left:311.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Sulphonylurea</span></p>
<p style="top:721.8pt;left:353.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Zimmerman et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">66</span></p>
<p style="top:634.6pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2005&#x2013;2014</span></p>
<p style="top:571.2pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">105 862</span></p>
<p style="top:514.5pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA, non-GLP-</span></p>
<p style="top:505.5pt;left:366.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">1RA</span></p>
<p style="top:416.0pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">8 362</span></p>
<p style="top:346.8pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.82 (0.74&#x2013;0.91)</span></p>
<p style="top:215.9pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.82 (0.74&#x2013;0.91)</span></p>
<p style="top:131.6pt;left:355.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Non-GLP-1RA</span></p>
<p style="top:721.8pt;left:375.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Anyanwagu et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">86</span></p>
<p style="top:634.6pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2006&#x2013;2014</span></p>
<p style="top:571.2pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">3 586</span></p>
<p style="top:514.5pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Insulin &amp; GLP-1RA,</span></p>
<p style="top:505.5pt;left:388.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">insulin</span></p>
<p style="top:416.0pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">1793</span></p>
<p style="top:346.8pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.76 (0.41&#x2013;1.42)</span></p>
<p style="top:215.9pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.93 (0.54&#x2013;1.61)</span></p>
<p style="top:131.6pt;left:377.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Insulin</span></p>
<p style="top:721.8pt;left:397.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">O&#x2019;Brien et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">64</span></p>
<p style="top:634.6pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2011&#x2013;2015</span></p>
<p style="top:571.2pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">132 737</span></p>
<p style="top:514.5pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA, DPP-4i,</span></p>
<p style="top:505.5pt;left:410.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">SGLT-2i, TZD, SFU,</span></p>
<p style="top:505.5pt;left:421.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">insulin</span></p>
<p style="top:416.0pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">11 351</span></p>
<p style="top:346.8pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.78 (0.63&#x2013;0.96)</span></p>
<p style="top:215.9pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.65 (0.44&#x2013;0.97)</span></p>
<p style="top:131.6pt;left:399.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">DPP-4i</span></p>
<p style="top:721.8pt;left:430.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Svanstrom et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">67</span></p>
<p style="top:634.6pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2010&#x2013;2016</span></p>
<p style="top:571.2pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">46 804</span></p>
<p style="top:514.5pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Liraglutide, DPP-4i</span></p>
<p style="top:416.0pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">23 402</span></p>
<p style="top:346.8pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.90 (0.83&#x2013;0.98)</span></p>
<p style="top:215.9pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.88 (0.77&#x2013;1.01)</span></p>
<p style="top:131.6pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">DPP-4i</span></p>
<p style="top:721.8pt;left:441.8pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Raparelli et al.</span><span style="font-family:AdvP7D09,serif;font-size:6.4pt">69</span></p>
<p style="top:634.6pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">2011&#x2013;2017</span></p>
<p style="top:571.2pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">167 254</span></p>
<p style="top:514.5pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">GLP-1RA, DPP-4i,</span></p>
<p style="top:505.5pt;left:454.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">SGLT-2i, SFU</span></p>
<p style="top:416.0pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">14 697</span></p>
<p style="top:346.8pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.70 (0.62&#x2013;0.78)</span></p>
<p style="top:346.8pt;left:454.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">Women only:</span></p>
<p style="top:346.8pt;left:465.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">0.57 (0.48&#x2013;0.68)</span></p>
<p style="top:215.9pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">NR</span></p>
<p style="top:131.6pt;left:443.6pt;line-height:9.0pt"><span style="font-family:AdvP7D09,serif;font-size:9.0pt">SFU</span></p>
<p style="top:722.6pt;left:480.2pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">Note: Frison et al.</span><span style="font-family:AdvP7D09,serif;font-size:5.7pt">87</span><span style="font-family:AdvP7D09,serif;font-size:8.0pt"> excluded as too small to calculate HR. NR: Not recorded; DPP-4i: dipeptidyl peptidase-4 inhibitor; SFU: sulphonylurea; SGLT-2i: sodium-glucose cotransporter-2 inhibitor; TZD:</span></p>
<p style="top:722.6pt;left:493.7pt;line-height:8.0pt"><span style="font-family:AdvP7D09,serif;font-size:8.0pt">thiazolidinedione.</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">25</span></p>


<p style="top:72.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tolerable in AIS patients and did not worsen functional</span></p>
<p style="top:85.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or neurological outcome. This study was not suf&#xfb01;cient-</span></p>
<p style="top:97.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ly powered to assess for improvement in stroke</span></p>
<p style="top:109.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes.</span></p>
<p style="top:121.8pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Larsson et al. report on PROLOGUES, a rando-</span></p>
<p style="top:134.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mised controlled trial comparing pre-hospital adminis-</span></p>
<p style="top:146.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tration</span></p>
<p style="top:146.4pt;left:90.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:146.4pt;left:111.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exenatide</span></p>
<p style="top:146.4pt;left:163.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with</span></p>
<p style="top:146.4pt;left:193.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">standard</span></p>
<p style="top:146.4pt;left:242.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">care</span></p>
<p style="top:146.4pt;left:272.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for</span></p>
<p style="top:158.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hyperglycemia in patients with suspected stroke.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">71</span></sup></p>
<p style="top:170.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nineteen patients were randomised, of an intended</span></p>
<p style="top:183.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">forty two, with eight of them receiving exenatide. The</span></p>
<p style="top:195.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trial was stopped early due to slow inclusion&#x2014;due to</span></p>
<p style="top:207.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">baseline glucose criteria and obtaining informed con-</span></p>
<p style="top:220.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sent. No associated adverse events were reported.</span></p>
<p style="top:232.2pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Results are awaited for two prospective studies. The</span></p>
<p style="top:244.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Short-Term</span></p>
<p style="top:244.5pt;left:108.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">EXenatide</span></p>
<p style="top:244.5pt;left:161.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:244.5pt;left:178.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Acute</span></p>
<p style="top:244.5pt;left:212.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ischemic</span></p>
<p style="top:244.5pt;left:256.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke</span></p>
<p style="top:256.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(STEXAS) trial</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">72</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">is a randomised, open-label, paral-</span></p>
<p style="top:269.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lel-group pilot study to investigate the ef&#xfb01;cacy of exe-</span></p>
<p style="top:281.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">natide in lowering blood glucose levels in patients with</span></p>
<p style="top:293.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AIS and hyperglycemia. They plan to recruit 30</span></p>
<p style="top:306.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">patients with AIS to either insulin or exenatide for up</span></p>
<p style="top:318.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to 72 h. They will assess feasibility of administration,</span></p>
<p style="top:330.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">incidence of hypoglycemia and functional outcomes at</span></p>
<p style="top:342.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">three months.</span></p>
<p style="top:354.8pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The Treatment with EXenatide in Acute Ischemic</span></p>
<p style="top:367.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stroke (TEXAIS) trial</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">73</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">is a three-year, phase 2,</span></p>
<p style="top:379.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">multi-centre,</span></p>
<p style="top:379.4pt;left:113.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">prospective,</span></p>
<p style="top:379.4pt;left:174.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">randomised,</span></p>
<p style="top:379.4pt;left:237.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">open-label,</span></p>
<p style="top:391.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blinded end-point trial comparing exenatide to stan-</span></p>
<p style="top:404.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dard care and aims to be powered to detect a change</span></p>
<p style="top:416.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in neurological outcome. Primary end-point is de&#xfb01;ned</span></p>
<p style="top:428.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as major neurological improvement at seven days (</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">8</span></p>
<p style="top:440.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">point improvement in NIHSS score, or score 0&#x2013;1). In</span></p>
<p style="top:453.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">contrast to STEXAS, this study will include patients</span></p>
<p style="top:465.6pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">independent of their glycemic status.</span></p>
<p style="top:493.4pt;left:49.6pt;line-height:12.0pt"><span style="font-family:AdvP7D0F,serif;font-size:12.0pt">Discussion</span></p>
<p style="top:512.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">As survival following stroke increases, so does the</span></p>
<p style="top:524.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">impact of post-stroke disability. Alongside the ongoing</span></p>
<p style="top:536.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">development in reperfusion therapies as part of the</span></p>
<p style="top:549.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gold standard of stroke care, a safe, widely applicable,</span></p>
<p style="top:561.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">well-tolerated and cost-effective neuroprotective agent</span></p>
<p style="top:573.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">becomes increasingly attractive.</span></p>
<p style="top:585.6pt;left:61.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We report a systematic review of the pre-clinical</span></p>
<p style="top:597.9pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research to support the neuroprotective properties of</span></p>
<p style="top:610.2pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RAs targeting the ischemic-reperfusion injury in</span></p>
<p style="top:622.5pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animal models of AIS. These have been shown to be</span></p>
<p style="top:634.8pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">safe and effective in normoglycemic models and dem-</span></p>
<p style="top:647.1pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onstrate neuroprotective outcomes by way of reduced</span></p>
<p style="top:659.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">infarct volume, apoptosis, oxidative stress, in&#xfb02;amma-</span></p>
<p style="top:671.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion and increased neurogenesis, angiogenesis and cere-</span></p>
<p style="top:684.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bral blood &#xfb02;ow. Crucially, they have demonstrated an</span></p>
<p style="top:696.3pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement</span></p>
<p style="top:696.3pt;left:115.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:696.3pt;left:132.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">post-stroke</span></p>
<p style="top:696.3pt;left:189.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">functional</span></p>
<p style="top:696.3pt;left:241.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes,</span></p>
<p style="top:708.7pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">including</span></p>
<p style="top:708.7pt;left:98.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">within</span></p>
<p style="top:708.7pt;left:134.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">both</span></p>
<p style="top:708.7pt;left:164.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">locomotive</span></p>
<p style="top:708.7pt;left:220.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:708.7pt;left:246.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cognitive</span></p>
<p style="top:721.0pt;left:49.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">domains.</span></p>
<p style="top:72.8pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In keeping with the real-world potential of GLP-</span></p>
<p style="top:84.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1RAs as a neuroprotectant in the management of</span></p>
<p style="top:96.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AIS, pre-clinical trials have now demonstrated repro-</span></p>
<p style="top:108.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ducible bene&#xfb01;ts in normoglycemic models with delayed</span></p>
<p style="top:120.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">administration up to 24 h after stroke induction.</span></p>
<p style="top:132.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Their neuroprotective mechanism is not fully under-</span></p>
<p style="top:144.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stood, with further research required. However, emerg-</span></p>
<p style="top:156.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing trends towards both GLP-1R-dependent, and</span></p>
<p style="top:168.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">independent, pathways have been reported. Following</span></p>
<p style="top:180.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">direct comparison studies with metformin and insulin,</span></p>
<p style="top:192.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their effects are due to more than restoration of glucose</span></p>
<p style="top:204.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">homeostasis. Additional research is required to fully</span></p>
<p style="top:216.8pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">understand the role of cleaved GLP-1 subunits, includ-</span></p>
<p style="top:228.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing GLP-1</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">[28&#x2013;36]</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">and could go some way to explain the</span></p>
<p style="top:240.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">difference in stroke reduction between GLP-1RAs in</span></p>
<p style="top:252.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">CVOTs.</span></p>
<p style="top:264.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The economic bene&#xfb01;ts of repurposing existing treat-</span></p>
<p style="top:276.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ments should not be overlooked, especially as the</span></p>
<p style="top:288.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">CVOTs</span></p>
<p style="top:288.9pt;left:340.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">have</span></p>
<p style="top:288.9pt;left:371.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated</span></p>
<p style="top:288.9pt;left:440.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their</span></p>
<p style="top:288.9pt;left:470.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cardiovascular</span></p>
<p style="top:300.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">safety, alongside a reduced incidence of non-fatal</span></p>
<p style="top:312.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke. Retrospective database studies show a trend</span></p>
<p style="top:324.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">towards a reduction in cardiovascular events, providing</span></p>
<p style="top:336.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">an important perspective from &#x2018;real-world&#x2019; usage.</span></p>
<p style="top:348.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Prospective clinical trials of GLP-1RAs in stroke are</span></p>
<p style="top:360.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ongoing, with initial outcomes suggestive of safety, tol-</span></p>
<p style="top:372.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">erability and that GLP-1RAs are feasibly administered</span></p>
<p style="top:384.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in the AIS cohort.</span></p>
<p style="top:396.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The</span></p>
<p style="top:396.9pt;left:334.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">comparative</span></p>
<p style="top:396.9pt;left:396.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effectiveness</span></p>
<p style="top:396.9pt;left:457.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:396.9pt;left:475.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction</span></p>
<p style="top:396.9pt;left:524.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:408.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">overall cardiovascular risk with newer antidiabetic</span></p>
<p style="top:420.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatments,</span></p>
<p style="top:420.9pt;left:356.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">such</span></p>
<p style="top:420.9pt;left:385.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">as</span></p>
<p style="top:420.9pt;left:405.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RAs,</span></p>
<p style="top:420.9pt;left:466.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sodium-glucose</span></p>
<p style="top:432.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">co-transporter-2 (SGLT-2) inhibitors and DPP-4 inhib-</span></p>
<p style="top:444.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">itors is unclear. However, a recent network meta-</span></p>
<p style="top:456.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">analysis has shown that only GLP-1RAs reduced</span></p>
<p style="top:468.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">non-fatal stroke incidence (OR 0.88, 95% CI 0.77&#x2013;</span></p>
<p style="top:480.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">0.99).</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">74</span></sup></p>
<p style="top:492.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We acknowledge the limitations of this study. Pre-</span></p>
<p style="top:504.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical</span></p>
<p style="top:504.9pt;left:337.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:504.9pt;left:376.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:504.9pt;left:405.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">generally</span></p>
<p style="top:504.9pt;left:453.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">conducted</span></p>
<p style="top:504.9pt;left:507.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on</span></p>
<p style="top:516.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">homogenous population of young animals without rep-</span><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">a</span></sup></p>
<p style="top:528.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resenting the co-morbidities often af&#xfb02;icting the human</span></p>
<p style="top:540.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stroke population. However, one study did demon-</span></p>
<p style="top:552.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strate comparable neuroprotective outcomes in both</span></p>
<p style="top:564.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">young mice and older, obese, diabetic models.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">25</span></sup></p>
<p style="top:576.9pt;left:309.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Further research into the impact of factors such as</span></p>
<p style="top:588.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">age, hypertension and gender is required. In addition,</span></p>
<p style="top:600.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies relied on a uniform etiology of stroke onset,</span></p>
<p style="top:612.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vascular territory and duration of occlusion &#x2013; constants</span></p>
<p style="top:624.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">which are not representative of the diverse, heteroge-</span></p>
<p style="top:636.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nous clinical manifestation of AIS. However, the inter-</span></p>
<p style="top:648.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study differences in stroke induction protocols (e.g.</span></p>
<p style="top:660.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">unilateral vs. bilateral, duration and vessel occlusion)</span></p>
<p style="top:672.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">do provide some mitigation to this. Furthermore, some</span></p>
<p style="top:685.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies utilized simultaneous bilateral occlusion of the</span></p>
<p style="top:696.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">carotid arteries to cause global ischemia which would</span></p>
<p style="top:708.9pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not normally occur in human stroke; however, this</span></p>
<p style="top:721.0pt;left:297.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">does still provide a valuable model of ischemic injury.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">26</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:72.8pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We also acknowledge the effect of publication bias</span></p>
<p style="top:85.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">favouring positive outcome and the limitations pre-</span></p>
<p style="top:97.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sented by the results of our STAIR and ARRIVE</span></p>
<p style="top:110.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">assessments. The potential for under-powered research</span></p>
<p style="top:122.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is appreciated.</span></p>
<p style="top:134.7pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Overall,</span></p>
<p style="top:134.7pt;left:118.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pre-clinical</span></p>
<p style="top:134.7pt;left:175.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:134.7pt;left:214.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are</span></p>
<p style="top:134.7pt;left:237.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">restricted</span></p>
<p style="top:134.7pt;left:287.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by</span></p>
<p style="top:147.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">small</span></p>
<p style="top:147.1pt;left:94.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">numbers,</span></p>
<p style="top:147.1pt;left:143.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">limited</span></p>
<p style="top:147.1pt;left:181.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">standardisation,</span></p>
<p style="top:147.1pt;left:260.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">disparity</span></p>
<p style="top:159.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between study dose and the licensed clinical dose and</span></p>
<p style="top:172.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">having a limited ability to replicate the numerous con-</span></p>
<p style="top:184.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">founding variables encountered in real-world stroke</span></p>
<p style="top:196.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">practice.</span></p>
<p style="top:209.0pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Of course, CVOTs report stroke incidence rather</span></p>
<p style="top:221.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">than stroke outcome. Other limitations include short</span></p>
<p style="top:233.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trial duration, complex multi-morbid patient character-</span></p>
<p style="top:246.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">istics, and the potential for pharmacological interac-</span></p>
<p style="top:258.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tions</span></p>
<p style="top:258.8pt;left:96.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with</span></p>
<p style="top:258.8pt;left:129.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">concomitant</span></p>
<p style="top:258.8pt;left:196.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">medications</span></p>
<p style="top:258.8pt;left:260.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">affecting</span></p>
<p style="top:271.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes. GLP-1RAs are known to reduce blood pres-</span></p>
<p style="top:283.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sure, body weight and cholesterol, all potentially miti-</span></p>
<p style="top:296.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gating stroke risk. Analysis of strokes occurring within</span></p>
<p style="top:308.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the REWIND trial demonstrated a reduction in stroke</span></p>
<p style="top:321.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">incidence, but no impact on stroke severity as measured</span></p>
<p style="top:333.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by mRS.</span></p>
<p style="top:345.5pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Retrospective studies generally included large num-</span></p>
<p style="top:358.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bers and are based upon real-world use and adherence.</span></p>
<p style="top:370.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">They reported encouraging results, often demonstrat-</span></p>
<p style="top:382.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing a reduction in cardiovascular risk and/or a modest</span></p>
<p style="top:395.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduction in stroke risk. Eloquent attempts were</span></p>
<p style="top:407.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">often made to adjust for confounding variables, but</span></p>
<p style="top:420.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">these do remain a signi&#xfb01;cant limitation, as does incom-</span></p>
<p style="top:432.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">plete extraction of events from databases.</span><sup><span style="font-family:Times New Roman,serif;font-size:7.1pt">66</span></sup><sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt">These</span></p>
<p style="top:445.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies are also limited by heterogeneity in treatment</span></p>
<p style="top:457.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">duration, dose, and by the grouping together of</span></p>
<p style="top:470.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">GLP-1RAs.</span></p>
<p style="top:482.1pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">There remains an unful&#xfb01;lled requirement for neuro-</span></p>
<p style="top:494.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protective</span></p>
<p style="top:494.5pt;left:115.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">agents</span></p>
<p style="top:494.5pt;left:152.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:494.5pt;left:170.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:494.5pt;left:194.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">management</span></p>
<p style="top:494.5pt;left:258.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:494.5pt;left:277.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AIS.</span></p>
<p style="top:507.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ultimately, many agents have previously failed to</span></p>
<p style="top:519.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">translate from bench to bedside.</span></p>
<p style="top:531.4pt;left:74.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">However, we propose that further research into the</span></p>
<p style="top:543.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">repurposing GLP-1RAs &#x2013; already licensed, with estab-</span></p>
<p style="top:556.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lished side-effect pro&#xfb01;les, cardiovascular safety record</span></p>
<p style="top:568.8pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and clear indicators from pre-clinical research of</span></p>
<p style="top:581.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their functional bene&#xfb01;t &#x2013; is both potentially clinically</span></p>
<p style="top:593.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and</span></p>
<p style="top:593.7pt;left:86.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">economically</span></p>
<p style="top:593.7pt;left:151.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">advantageous.</span></p>
<p style="top:593.7pt;left:220.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Further</span></p>
<p style="top:593.7pt;left:262.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research</span></p>
<p style="top:606.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is</span></p>
<p style="top:606.2pt;left:79.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">required</span></p>
<p style="top:606.2pt;left:125.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to</span></p>
<p style="top:606.2pt;left:145.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">establish</span></p>
<p style="top:606.2pt;left:192.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">optimal</span></p>
<p style="top:606.2pt;left:235.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dosing,</span></p>
<p style="top:606.2pt;left:277.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cost-</span></p>
<p style="top:618.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effectiveness, interaction with reperfusion therapies,</span></p>
<p style="top:631.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">timing of administration, and to fully understand the</span></p>
<p style="top:643.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">underlying mechanism of action &#x2013; with consideration</span></p>
<p style="top:656.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of age, gender and co-morbidity &#x2013; in order to guide</span></p>
<p style="top:668.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">larger clinical trial development.</span></p>
<p style="top:692.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Funding</span></p>
<p style="top:709.3pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">The author(s) received no &#xfb01;nancial support for the research,</span></p>
<p style="top:721.8pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">authorship, and/or publication of this article.</span></p>
<p style="top:72.7pt;left:310.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Declaration of conflicting interests</span></p>
<p style="top:89.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">The author(s) declared the following potential con&#xfb02;icts of</span></p>
<p style="top:101.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">interest with respect to the research, authorship, and/or pub-</span></p>
<p style="top:113.9pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lication of this article: CH is a named inventor on several</span></p>
<p style="top:126.1pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">patent applications that cover the use of GLP-1RAs for the</span></p>
<p style="top:138.3pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">treatment of neurodegenerative disorders. WDS has received</span></p>
<p style="top:150.4pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">speaker honoraria, conference sponsorship by Astra-Zeneca,</span></p>
<p style="top:162.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Boehringer</span></p>
<p style="top:162.6pt;left:361.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Ingelheim,</span></p>
<p style="top:162.6pt;left:410.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Bristol</span></p>
<p style="top:162.6pt;left:444.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Myers</span></p>
<p style="top:162.6pt;left:477.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Squibb,</span></p>
<p style="top:162.6pt;left:515.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Colgate</span></p>
<p style="top:174.8pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Palmolive,</span></p>
<p style="top:174.8pt;left:364.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Eli</span></p>
<p style="top:174.8pt;left:388.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Lilly,</span></p>
<p style="top:174.8pt;left:421.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GlaxoSmithKline,</span></p>
<p style="top:174.8pt;left:504.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Lundbeck,</span></p>
<p style="top:187.0pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Menarini, Merck, Novartis, Novo Nordisk, P&#xfb01;zer, Sano&#xfb01;</span></p>
<p style="top:199.1pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Aventis, Servier, and Takeda. He holds research grants</span></p>
<p style="top:211.3pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">from Astra-Zeneca, Novo Nordisk and Novartis.</span></p>
<p style="top:234.5pt;left:310.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Authors&#x2019; contributions</span></p>
<p style="top:249.3pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">All authors contributed to the study conception and design.</span></p>
<p style="top:260.4pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Material preparation, data collection and analysis were per-</span></p>
<p style="top:271.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">formed by MM and HE. The &#xfb01;rst draft of the manuscript was</span></p>
<p style="top:282.8pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">written by MM and all authors commented on previous ver-</span></p>
<p style="top:294.0pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sions of the manuscript. All authors read and approved the</span></p>
<p style="top:305.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">&#xfb01;nal manuscript.</span></p>
<p style="top:328.1pt;left:310.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">Ethical approval</span></p>
<p style="top:342.9pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">This systematic review does not contain any new studies with</span></p>
<p style="top:354.1pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">human participants or animal performed by any of the</span></p>
<p style="top:365.3pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">authors.</span></p>
<p style="top:388.2pt;left:310.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">ORCID iDs</span></p>
<p style="top:403.0pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Mark P Maskery</span></p>
<p style="top:403.0pt;left:392.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">https://orcid.org/0000-0001-5661-6267</span></p>
<p style="top:414.0pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Christian Holscher</span></p>
<p style="top:414.0pt;left:398.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">https://orcid.org/0000-0002-8159-3260</span></p>
<p style="top:440.0pt;left:310.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0F,serif;font-size:10.0pt">References</span></p>
<p style="top:454.8pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1. Feigin VL, Norrving B and Mensah GA. Global burden</span></p>
<p style="top:466.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Circ Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 120: 439&#x2013;448.</span></p>
<p style="top:477.0pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al.</span></p>
<p style="top:488.1pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Global and regional burden of stroke during 1990&#x2013;</span></p>
<p style="top:499.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2010: &#xfb01;ndings from the Global Burden of Disease</span></p>
<p style="top:510.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Study 2010.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 383: 245&#x2013;255.</span></p>
<p style="top:521.5pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3. McMeekin P, White P, James MA, et al. Estimating the</span></p>
<p style="top:532.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">number of UK stroke patients eligible for endovascular</span></p>
<p style="top:543.8pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">thrombectomy.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Eur Stroke J</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 2: 319&#x2013;326.</span></p>
<p style="top:554.8pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">4. Goyal</span></p>
<p style="top:554.8pt;left:358.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">M,</span></p>
<p style="top:554.8pt;left:378.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Menon</span></p>
<p style="top:554.8pt;left:414.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">BK,</span></p>
<p style="top:554.8pt;left:438.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">van</span></p>
<p style="top:554.8pt;left:461.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Zwam</span></p>
<p style="top:554.8pt;left:493.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">WH,</span></p>
<p style="top:554.8pt;left:521.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:554.8pt;left:536.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:566.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Endovascular thrombectomy after large-vessel ischaemic</span></p>
<p style="top:577.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">stroke: a meta-analysis of individual patient data from</span></p>
<p style="top:588.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">&#xfb01;ve randomised trials.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 387: 1723&#x2013;1731.</span></p>
<p style="top:599.4pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">5. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for</span></p>
<p style="top:610.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acute ischaemic stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Cochrane Database Syst Rev</span></p>
<p style="top:621.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2014; 7: 18.</span></p>
<p style="top:632.7pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">6. Neuhaus</span></p>
<p style="top:632.7pt;left:371.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">AA,</span></p>
<p style="top:632.7pt;left:399.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Couch</span></p>
<p style="top:632.7pt;left:436.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Y,</span></p>
<p style="top:632.7pt;left:457.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Hadley</span></p>
<p style="top:632.7pt;left:496.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">G,</span></p>
<p style="top:632.7pt;left:517.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:632.7pt;left:536.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:643.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroprotection in stroke: the importance of collabora-</span></p>
<p style="top:655.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tion and reproducibility.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Brain</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 140: 2079&#x2013;2092.</span></p>
<p style="top:666.0pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">7. Fisher M, Feuerstein G, Howells DW, et al. Update of</span></p>
<p style="top:677.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the stroke therapy academic industry roundtable preclin-</span></p>
<p style="top:688.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ical recommendations.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 40: 2244&#x2013;2250.</span></p>
<p style="top:699.4pt;left:314.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">8. Shi S, M</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">orike K and Klotz U. The clinical implications</span></p>
<p style="top:710.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of ageing for rational drug therapy.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Eur J Clin Pharmacol</span></p>
<p style="top:721.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2008; 64: 183&#x2013;199.</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">27</span></p>


<p style="top:73.0pt;left:54.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">9. Hurn PD, Vannucci SJ and Hagberg H. Adult or perina-</span></p>
<p style="top:84.2pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tal brain injury: does sex matter?</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2005; 36:</span></p>
<p style="top:95.5pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">193&#x2013;195.</span></p>
<p style="top:106.5pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">10. O&#x2019;Collins VE, Macleod MR, Donnan GA, et al. 1,026</span></p>
<p style="top:117.7pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Experimental treatments in acute stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Ann Neurol</span></p>
<p style="top:129.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2006; 59: 467&#x2013;477.</span></p>
<p style="top:140.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">11. Sutherland</span></p>
<p style="top:140.0pt;left:116.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">BA,</span></p>
<p style="top:140.0pt;left:140.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Minnerup</span></p>
<p style="top:140.0pt;left:188.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J,</span></p>
<p style="top:140.0pt;left:203.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Balami</span></p>
<p style="top:140.0pt;left:239.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">JS,</span></p>
<p style="top:140.0pt;left:259.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:140.0pt;left:275.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:151.3pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroprotection for ischaemic stroke: translation from</span></p>
<p style="top:162.5pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the bench to the bedside.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Int J Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 7: 407&#x2013;418.</span></p>
<p style="top:173.5pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">12. H</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">olscher C. Potential role of glucagon-like peptide-1</span></p>
<p style="top:184.8pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">(GLP-1) in neuroprotection.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> CNS Drugs</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 26:</span></p>
<p style="top:196.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">871&#x2013;882.</span></p>
<p style="top:207.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">13. Gallwitz B. Extra-pancreatic effects of incretin-based</span></p>
<p style="top:218.3pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">therapies.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Endocrine</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 47: 360&#x2013;371.</span></p>
<p style="top:229.3pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">14. H</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">olscher C. Central effects of GLP-1: new opportunities</span></p>
<p style="top:240.5pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">for</span></p>
<p style="top:240.5pt;left:87.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">treatments</span></p>
<p style="top:240.5pt;left:138.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of</span></p>
<p style="top:240.5pt;left:156.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">neurodegenerative</span></p>
<p style="top:240.5pt;left:237.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diseases.</span></p>
<p style="top:240.5pt;left:280.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J</span></p>
<p style="top:251.8pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Endocrinol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 221: T31&#x2013;T41.</span></p>
<p style="top:262.8pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">15. Boland A, Cherry G and Dickson R.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Doing a systematic</span></p>
<p style="top:274.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">review:</span></p>
<p style="top:274.0pt;left:100.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">a</span></p>
<p style="top:274.0pt;left:113.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">student&#x2019;s</span></p>
<p style="top:274.0pt;left:154.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">guide</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">.</span></p>
<p style="top:274.0pt;left:185.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1st</span></p>
<p style="top:274.0pt;left:205.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ed.</span></p>
<p style="top:274.0pt;left:225.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">London:</span></p>
<p style="top:274.0pt;left:267.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Sage</span></p>
<p style="top:285.3pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Publications, 2013.</span></p>
<p style="top:296.3pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">16. Kilkenny C, Browne WJ, Cuthill IC, et al. Improving</span></p>
<p style="top:307.6pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">bioscience research reporting: the ARRIVE Guidelines</span></p>
<p style="top:318.8pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">for Reporting Animal Research.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> PLoS Biol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 8:</span></p>
<p style="top:330.1pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">e1000412.</span></p>
<p style="top:341.1pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">17. Hyun Lee C, Yan B, Yoo K-Y, et al. Ischemia-induced</span></p>
<p style="top:352.3pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">changes in glucagon-like peptide-1 receptor and neuro-</span></p>
<p style="top:363.6pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">protective effect of its agonist, exendin-4, in experimental</span></p>
<p style="top:374.8pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">transient cerebral ischemia.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J Neurosci Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 89:</span></p>
<p style="top:386.1pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1103&#x2013;1113.</span></p>
<p style="top:397.1pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">18. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimu-</span></p>
<p style="top:408.3pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lation preserves primary cortical and dopaminergic neu-</span></p>
<p style="top:419.6pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rons in cellular and rodent models of stroke and</span></p>
<p style="top:430.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Parkinsonism.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Proc Natl Acad Sci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2009; 106: 1285&#x2013;1290.</span></p>
<p style="top:441.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">19. Briyal S, Gulati K and Gulati A. Repeated administra-</span></p>
<p style="top:453.1pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tion of exendin-4 reduces focal cerebral ischemia-induced</span></p>
<p style="top:464.4pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">infarction in rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Brain Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 1427: 23&#x2013;34.</span></p>
<p style="top:475.4pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">20. Darsalia V, Mansouri S, Orts</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">ater H, et al. Glucagon-like</span></p>
<p style="top:486.6pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">peptide-1 receptor activation reduces ischaemic brain</span></p>
<p style="top:497.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">damage following stroke in Type 2 diabetic rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Clin</span></p>
<p style="top:509.1pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Sci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 122: 473&#x2013;483.</span></p>
<p style="top:520.1pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">21. Jia Y, Gong N, Li T-F, et al. Peptidic exenatide and</span></p>
<p style="top:531.4pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">herbal catalpol mediate neuroprotection via the hippo-</span></p>
<p style="top:542.6pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">campal</span></p>
<p style="top:542.6pt;left:109.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GLP-1</span></p>
<p style="top:542.6pt;left:151.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">receptor/</span><span style="font-family:AdvPSMP10,serif;font-size:9.0pt">b</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">-endorphin</span></p>
<p style="top:542.6pt;left:249.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">pathway.</span></p>
<p style="top:553.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharmacol Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 102: 276&#x2013;285.</span></p>
<p style="top:564.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">22. Zhang H, Meng J, Zhou S, et al. Intranasal delivery of</span></p>
<p style="top:576.2pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">exendin-4 confers neuroprotective effect against cerebral</span></p>
<p style="top:587.4pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ischemia in mice.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> AAPS J</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 18: 385&#x2013;394.</span></p>
<p style="top:598.4pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">23. Kim S, Jeong J, Jung H-S, et al. Anti-in&#xfb02;ammatory effect</span></p>
<p style="top:609.7pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of glucagon like peptide-1 receptor agonist, exendin-4,</span></p>
<p style="top:620.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">through modulation of IB1/JIP1 expression and JNK sig-</span></p>
<p style="top:632.2pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">naling in stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Exp Neurobiol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 26: 227.</span></p>
<p style="top:643.2pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">24. Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a</span></p>
<p style="top:654.4pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">glucagon-like peptide-1 receptor agonist, provides neuro-</span></p>
<p style="top:665.7pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">protection in mice transient focal cerebral ischemia.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J</span></p>
<p style="top:676.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cereb Blood Flow Metab</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 31: 1696&#x2013;1705.</span></p>
<p style="top:687.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">25. Darsalia V, Hua S, Larsson M, et al. Exendin-4 reduces</span></p>
<p style="top:699.2pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ischemic brain injury in normal and aged type 2 diabetic</span></p>
<p style="top:710.5pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mice and promotes microglial M2 polarization.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> PLoS</span></p>
<p style="top:721.7pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ONE</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 9: e103114.</span></p>
<p style="top:72.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">26. Chen F, Wang W, Ding H, et al. The glucagon-like pep-</span></p>
<p style="top:84.2pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tide-1 receptor agonist exendin-4 ameliorates warfarin-</span></p>
<p style="top:95.5pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">associated hemorrhagic transformation after cerebral</span></p>
<p style="top:106.7pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ischemia.</span></p>
<p style="top:106.7pt;left:360.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J</span></p>
<p style="top:106.7pt;left:377.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroin&#xfb02;ammation</span></p>
<p style="top:106.7pt;left:461.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2016;</span></p>
<p style="top:106.7pt;left:493.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">13:</span></p>
<p style="top:106.7pt;left:517.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">204.</span></p>
<p style="top:117.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">DOI:10.1186/s12974-016-0661-0.</span></p>
<p style="top:128.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">27. Kuroki T, Tanaka R, Shimada Y, et al. Exendin-4 inhib-</span></p>
<p style="top:140.2pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">its matrix metalloproteinase-9 activation and reduces</span></p>
<p style="top:151.4pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">infarct growth after focal cerebral ischemia in hypergly-</span></p>
<p style="top:162.6pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cemic mice.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 47: 1328&#x2013;1335.</span></p>
<p style="top:173.6pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">28. Yang J-L, Chen W-Y, Chen Y-P, et al. Activation of</span></p>
<p style="top:184.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GLP-1 receptor enhances neuronal base excision repair</span></p>
<p style="top:196.2pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">via PI3K-AKT-induced expression of apurinic/apyrimi-</span></p>
<p style="top:207.4pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">dinic endonuclease 1.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Theranostics</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 6: 2015&#x2013;2027.</span></p>
<p style="top:218.4pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">29. Briyal S, Shah S and Gulati A. Neuroprotective and anti-</span></p>
<p style="top:229.7pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">apoptotic effects of liraglutide in the rat brain following</span></p>
<p style="top:240.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">focal cerebral ischemia.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Neuroscience</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 281: 269&#x2013;281.</span></p>
<p style="top:251.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">30. Deng C, Cao J, Han J, et al. Liraglutide activates the</span></p>
<p style="top:263.2pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Nrf2/HO-1 antioxidant pathway and protects brain</span></p>
<p style="top:274.4pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">nerve cells against cerebral ischemia in diabetic rats.</span></p>
<p style="top:285.6pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Comput Intell Neurosci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 2018: 1&#x2013;7.</span></p>
<p style="top:296.6pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">31. Filchenko</span></p>
<p style="top:296.6pt;left:361.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">I,</span></p>
<p style="top:296.6pt;left:376.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Simanenkova</span></p>
<p style="top:296.6pt;left:437.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">A,</span></p>
<p style="top:296.6pt;left:457.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Chefu</span></p>
<p style="top:296.6pt;left:489.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">S,</span></p>
<p style="top:296.6pt;left:507.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:296.6pt;left:523.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:307.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuroprotective effect of glucagon-like peptide-1 receptor</span></p>
<p style="top:319.1pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">agonist is independent of glycaemia normalization in type</span></p>
<p style="top:330.3pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">two diabetic rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diab Vasc Dis Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 15: 567&#x2013;570.</span></p>
<p style="top:341.3pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">32. Sato K, Kameda M, Yasuhara T, et al. Neuroprotective</span></p>
<p style="top:352.6pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">effects of liraglutide for stroke model of rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Int J Mol</span></p>
<p style="top:363.8pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Sci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 14: 21513&#x2013;21524.</span></p>
<p style="top:374.8pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">33. Zhu H, Zhang Y, Shi Z, et al. The neuroprotection of</span></p>
<p style="top:386.1pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">liraglutide against ischaemia-induced apoptosis through</span></p>
<p style="top:397.4pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the activation of the PI3K/AKT and MAPK pathways.</span></p>
<p style="top:408.6pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Sci Rep</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 6: 26859. DOI:10.1038/srep26859.</span></p>
<p style="top:419.6pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">34. Dong W, Miao Y, Chen A, et al. Delayed administration</span></p>
<p style="top:430.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of the GLP-1 receptor agonist liraglutide improves met-</span></p>
<p style="top:442.1pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">abolic and functional recovery after cerebral ischemia in</span></p>
<p style="top:453.3pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Neurosci Lett</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 641: 1&#x2013;7.</span></p>
<p style="top:464.3pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">35. Chen Y, Zhang X, He J, et al. Delayed administration of</span></p>
<p style="top:475.6pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the glucagon-like peptide 1 analog liraglutide promoting</span></p>
<p style="top:486.8pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">angiogenesis after focal cerebral ischemia in mice.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J</span></p>
<p style="top:498.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Stroke Cerebrovasc Dis</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 27: 1318&#x2013;1325.</span></p>
<p style="top:509.0pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">36. He W, Wang H, Zhao C, et al. Role of liraglutide in brain</span></p>
<p style="top:520.3pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">repair promotion through Sirt1-mediated mitochondrial</span></p>
<p style="top:531.5pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">improvement</span></p>
<p style="top:531.5pt;left:371.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in</span></p>
<p style="top:531.5pt;left:386.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">stroke.</span></p>
<p style="top:531.5pt;left:419.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J</span></p>
<p style="top:531.5pt;left:431.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cell</span></p>
<p style="top:531.5pt;left:454.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Physiol</span></p>
<p style="top:531.5pt;left:489.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2020;</span></p>
<p style="top:531.5pt;left:517.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">235:</span></p>
<p style="top:542.8pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2986&#x2013;3001.</span></p>
<p style="top:553.8pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">37. Zeng S, Bai J, Jiang H, et al. Treatment with liraglutide</span></p>
<p style="top:565.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">exerts</span></p>
<p style="top:565.0pt;left:343.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">neuroprotection</span></p>
<p style="top:565.0pt;left:412.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">after</span></p>
<p style="top:565.0pt;left:437.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">hypoxic&#x2013;ischemic</span></p>
<p style="top:565.0pt;left:512.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">brain</span></p>
<p style="top:576.3pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">injury in neonatal rats via the PI3K/AKT/GSK3</span><span style="font-family:AdvPSMP10,serif;font-size:9.0pt">b</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> path-</span></p>
<p style="top:587.5pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">way.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Front Cell Neurosci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2020; 13: 585. DOI:10.3389/</span></p>
<p style="top:598.8pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">fncel.2019.00585.</span></p>
<p style="top:609.8pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">38. Jiang D, Wang Y, Zang Y, et al. Neuroprotective Effects</span></p>
<p style="top:621.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of rhGLP-1 in diabetic rats with cerebral ischemia/reper-</span></p>
<p style="top:632.3pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">fusion injury: rhGLP-1 neuroprotective bene&#xfb01;ts.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Drug</span></p>
<p style="top:643.5pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Dev Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 77: 124&#x2013;133.</span></p>
<p style="top:654.5pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">39. Fang Y, Jiang D, Wang Y, et al. Neuroprotection of</span></p>
<p style="top:665.7pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rhGLP-1 in diabetic rats with cerebral ischemia/reperfu-</span></p>
<p style="top:677.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sion injury via regulation of oxidative stress, EAAT2,</span></p>
<p style="top:688.2pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and apoptosis.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Drug Dev Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 79: 249&#x2013;259.</span></p>
<p style="top:699.2pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">40. Zhao L, Xu J, Wang Q, et al. Protective effect of rhGLP-</span></p>
<p style="top:710.5pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1 (7&#x2013;36) on brain ischemia/reperfusion damage in diabet-</span></p>
<p style="top:721.7pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ic rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Brain Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 1602: 153&#x2013;159.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">28</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>


<p style="top:73.0pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">41. Abdel-latif RG, Heeba GH, Taye A, et al. Lixisenatide</span></p>
<p style="top:84.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ameliorates</span></p>
<p style="top:84.2pt;left:129.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:84.2pt;left:168.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ischemia-reperfusion</span></p>
<p style="top:84.2pt;left:255.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">injury</span></p>
<p style="top:84.2pt;left:286.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">via</span></p>
<p style="top:95.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GLP-1 receptor dependent/independent pathways.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Eur</span></p>
<p style="top:106.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J Pharmacol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 833: 145&#x2013;154.</span></p>
<p style="top:117.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">42. Abdel-latif RG, Heeba GH, Taye A, et al. Lixisenatide, a</span></p>
<p style="top:129.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">novel GLP-1 analog, protects against cerebral ischemia/</span></p>
<p style="top:140.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">reperfusion injury in diabetic rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Naunyn Schmiedebergs</span></p>
<p style="top:151.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Arch Pharmacol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 391: 705&#x2013;717.</span></p>
<p style="top:162.5pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">43. Yang X, Feng P, Zhang X, et al. The diabetes drug sem-</span></p>
<p style="top:173.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">aglutide reduces infarct size, in&#xfb02;ammation, and apopto-</span></p>
<p style="top:185.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sis, and normalizes neurogenesis in a rat model of stroke.</span></p>
<p style="top:196.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Neuropharmacology</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 158: 107748.</span></p>
<p style="top:207.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">44. Chien C-T, Jou M-J, Cheng T-Y, et al. Exendin-4-loaded</span></p>
<p style="top:218.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">PLGA microspheres relieve cerebral ischemia/reperfusion</span></p>
<p style="top:229.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">injury and neurologic de&#xfb01;cits through long-lasting bioac-</span></p>
<p style="top:240.9pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tivity-mediated phosphorylated Akt/eNOS signaling in</span></p>
<p style="top:252.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rats.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J Cereb Blood Flow Metab</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 35: 1790&#x2013;1803.</span></p>
<p style="top:263.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">45. Zhang H, Meng J, Li X, et al. Pro-GLP-1, a Pro-drug of</span></p>
<p style="top:274.4pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GLP-1, is neuroprotective in cerebral ischemia.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Eur J</span></p>
<p style="top:285.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Pharm Sci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 70: 82&#x2013;91.</span></p>
<p style="top:296.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">46. Zhang H, Liu Y, Guan S, et al. An orally active allosteric</span></p>
<p style="top:307.9pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">GLP-1 receptor agonist is neuroprotective in cellular and</span></p>
<p style="top:319.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rodent models of stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> PLoS ONE</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 11: e0148827.</span></p>
<p style="top:330.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">47. Han L, Holscher C, Xue G, et al. A novel dual-glucagon-</span></p>
<p style="top:341.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">like peptide 1 and glucose-dependent insulinotrophic</span></p>
<p style="top:352.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">polypeptide receptor agonist is neuroprotective in tran-</span></p>
<p style="top:364.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">sient focal cerebral ischaemia in the rat.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Neuroreport</span></p>
<p style="top:375.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2016; 6: 23&#x2013;32.</span></p>
<p style="top:386.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">48. Li Y, Wu K-J, Yu S-J, et al. Neurotrophic and neuro-</span></p>
<p style="top:397.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">protective effects of oxyntomodulin in neuronal cells and</span></p>
<p style="top:408.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">a rat model of stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Exp Neurol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 288: 104&#x2013;113.</span></p>
<p style="top:419.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">49. Wang Y-H, Liou K-T, Tsai K-C, et al. GSK-3 inhibition</span></p>
<p style="top:431.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">through GLP-1R allosteric activation mediates the neu-</span></p>
<p style="top:442.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rogenesis promoting effect of P7C3 after cerebral ische-</span></p>
<p style="top:453.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mic/reperfusional injury in mice.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Toxicol Appl Pharmacol</span></p>
<p style="top:464.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2018; 357: 88&#x2013;105.</span></p>
<p style="top:475.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">50. Li P-C, Liu L-F, Jou M-J, et al. The GLP-1 receptor ago-</span></p>
<p style="top:487.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">nists exendin-4 and liraglutide alleviate oxidative stress and</span></p>
<p style="top:498.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cognitive and micturition de&#xfb01;cits induced by middle cere-</span></p>
<p style="top:509.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">bral artery occlusion in diabetic mice.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> BMC Neurosci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016;</span></p>
<p style="top:520.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">17: 50. DOI: 10.1186/s12868-016-0272-9.</span></p>
<p style="top:531.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">51. Gad SN, Nofal S, Raafat EM, et al. Lixisenatide reduced</span></p>
<p style="top:543.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">damage in hippocampus CA1 neurons in a rat model of</span></p>
<p style="top:554.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cerebral ischemia-reperfusion possibly via the ERK/P38</span></p>
<p style="top:565.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">signaling pathway.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J Mol Neurosci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2020; 70: 1026&#x2013;1037.</span></p>
<p style="top:576.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">DOI: 10.1007/s12031-020-01497-9.</span></p>
<p style="top:587.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">52. Pawlowski J and Kraft AS. Bax-induced apoptotic cell</span></p>
<p style="top:598.9pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">death.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Proc Natl Acad Sci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2000; 97: 529&#x2013;531.</span></p>
<p style="top:609.9pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">53. Chaitanya G, Alexander JS and Babu P. PARP-1 cleav-</span></p>
<p style="top:621.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">age fragments: signatures of cell-death proteases in neu-</span></p>
<p style="top:632.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rodegeneration.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Cell Commun Signal</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2010; 8: 31.</span></p>
<p style="top:643.4pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">54. Porter AG and J</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">anicke RU. Emerging roles of caspase-3</span></p>
<p style="top:654.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">in apoptosis.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Cell Death Differ</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 1999; 6: 99&#x2013;104.</span></p>
<p style="top:665.7pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">55. Darzynkiewicz Z, Galkowski D and Zhao H. Analysis of</span></p>
<p style="top:677.0pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">apoptosis by cytometry using TUNEL assay.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Methods</span></p>
<p style="top:688.2pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2008; 44: 250&#x2013;254.</span></p>
<p style="top:699.2pt;left:62.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">56. Wilkins HM and Swerdlow RH. TNF</span><span style="font-family:AdvPSMP10,serif;font-size:9.0pt">a</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> in cerebral ische-</span></p>
<p style="top:710.5pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mia: another stroke against you?</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J Neurochem</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 132:</span></p>
<p style="top:721.7pt;left:78.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">369&#x2013;372.</span></p>
<p style="top:72.9pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">57. Bell AH, Miller SL, Castillo-Melendez M, et al. The neu-</span></p>
<p style="top:84.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">rovascular unit: effects of brain insults during the perina-</span></p>
<p style="top:95.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tal period.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Front Neurosci</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2020; 13: 1452. DOI: 10.3389/</span></p>
<p style="top:106.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">fnins.2019.01452.</span></p>
<p style="top:117.7pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">58. Ma Y, Zechariah A, Qu Y, et al. Effects of vascular</span></p>
<p style="top:128.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">endothelial growth factor in ischemic stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> J Neurosci</span></p>
<p style="top:140.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Res</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2012; 90: 1873&#x2013;1882.</span></p>
<p style="top:151.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">59. Zhou B, Ji K, Peng A, et al. GLP-1(28-36)amide, a long</span></p>
<p style="top:162.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ignored peptide revisited.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Open Biochem J</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2014; 8:</span></p>
<p style="top:173.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">107&#x2013;111.</span></p>
<p style="top:184.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">60. Gerstein HC, Hart R, Colhoun HM, et al. The effect of</span></p>
<p style="top:195.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">dulaglutide on stroke: an exploratory analysis of the</span></p>
<p style="top:207.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">REWIND trial.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet Diab Endocrinol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2020; 8: 106&#x2013;114.</span></p>
<p style="top:218.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">61. Mann JFE, Fonseca V, Mosenzon O, et al. Effects of</span></p>
<p style="top:229.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">liraglutide versus placebo on cardiovascular events in</span></p>
<p style="top:240.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">patients with type 2 diabetes mellitus and chronic</span></p>
<p style="top:251.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">kidney</span></p>
<p style="top:251.9pt;left:360.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">disease:</span></p>
<p style="top:251.9pt;left:397.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">results</span></p>
<p style="top:251.9pt;left:430.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">from</span></p>
<p style="top:251.9pt;left:457.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the</span></p>
<p style="top:251.9pt;left:477.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">LEADER</span></p>
<p style="top:251.9pt;left:524.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Trial.</span></p>
<p style="top:263.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Circulation</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 138: 2908&#x2013;2918.</span></p>
<p style="top:274.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">62. Kang YM, Cho YK, Lee J, et al. Asian subpopulations</span></p>
<p style="top:285.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">may exhibit greater cardiovascular bene&#xfb01;t from long-</span></p>
<p style="top:296.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acting glucagon-like peptide 1 receptor agonists: a</span></p>
<p style="top:307.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">meta-analysis of cardiovascular outcome trials.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diabetes</span></p>
<p style="top:319.1pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Metab J</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 42.</span></p>
<p style="top:330.1pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">63. Barkas F, Elisaf M and Milionis H. Protection against</span></p>
<p style="top:341.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">stroke with glucagon-like peptide 1 receptor agonists: a</span></p>
<p style="top:352.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">systematic review and meta-analysis.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Eur J Neurol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019;</span></p>
<p style="top:363.8pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">26: 559&#x2013;565. DOI: 10.1111/ene.13905.</span></p>
<p style="top:374.8pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">64. O&#x2019;Brien MJ, Karam SL, Wallia A, et al. Association of</span></p>
<p style="top:386.1pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">second-line antidiabetic medications with cardiovascular</span></p>
<p style="top:397.4pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">events among insured adults with type 2 diabetes.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> JAMA</span></p>
<p style="top:408.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Netw Open</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 1: e186125.</span></p>
<p style="top:419.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">65. Paul SK, Klein K, Maggs D, et al. The association of the</span></p>
<p style="top:430.9pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">treatment with glucagon-like peptide-1 receptor agonist</span></p>
<p style="top:442.1pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">exenatide or insulin with cardiovascular outcomes in</span></p>
<p style="top:453.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">patients with type 2 diabetes: a retrospective observation-</span></p>
<p style="top:464.6pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Cardiovasc Diabetol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 14: 10.</span></p>
<p style="top:475.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">66. Zimmerman RS, Hobbs TM, Wells BJ, et al. Association</span></p>
<p style="top:486.8pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of glucagon-like peptide-1 receptor agonist use and rates</span></p>
<p style="top:498.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of acute myocardial infarction, stroke and overall mor-</span></p>
<p style="top:509.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tality in patients with type 2 diabetes mellitus in a large</span></p>
<p style="top:520.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">integrated health system.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diabetes Obes Metab</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 19:</span></p>
<p style="top:531.8pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">1555&#x2013;1561.</span></p>
<p style="top:542.8pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">67. Svanstr</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">om H, Ueda P, Melbye M, et al. Use of liraglutide</span></p>
<p style="top:554.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and risk of major cardiovascular events: a register based</span></p>
<p style="top:565.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cohort study in Denmark and Sweden.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet Diab</span></p>
<p style="top:576.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Endocrinol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 7: 106&#x2013;114.</span></p>
<p style="top:587.6pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">68. Anyanwagu U, Mamza J, Mehta R, et al. Cardiovascular</span></p>
<p style="top:598.8pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">events</span></p>
<p style="top:598.8pt;left:357.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and</span></p>
<p style="top:598.8pt;left:379.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">all-cause</span></p>
<p style="top:598.8pt;left:420.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mortality</span></p>
<p style="top:598.8pt;left:464.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">with</span></p>
<p style="top:598.8pt;left:488.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">insulin</span></p>
<p style="top:598.8pt;left:521.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">versus</span></p>
<p style="top:610.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">glucagon-like peptide-1 analogue in type 2 diabetes.</span></p>
<p style="top:621.3pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Heart</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 102: 1581&#x2013;1587.</span></p>
<p style="top:632.3pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">69. Raparelli V, Elharram M, Moura CS, et al. Sex differ-</span></p>
<p style="top:643.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ences in cardiovascular effectiveness of newer glucose-</span></p>
<p style="top:654.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">lowering drugs added to metformin in type 2 diabetes</span></p>
<p style="top:666.0pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mellitus.</span></p>
<p style="top:666.0pt;left:367.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">J</span></p>
<p style="top:666.0pt;left:381.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Am</span></p>
<p style="top:666.0pt;left:404.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Heart</span></p>
<p style="top:666.0pt;left:435.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Assoc</span></p>
<p style="top:666.0pt;left:466.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2020;</span></p>
<p style="top:666.0pt;left:496.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">9:</span></p>
<p style="top:666.0pt;left:512.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">e012940.</span></p>
<p style="top:677.2pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">doi:10.1161/JAHA.119.012940.</span></p>
<p style="top:688.2pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">70. Daly SC, Chemmanam T, Loh P-S, et al. Exenatide in</span></p>
<p style="top:699.5pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">acute ischemic stroke.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Int J Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2013; 8: E44&#x2013;E44.</span></p>
<p style="top:710.5pt;left:310.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">71. Larsson M, Castren M, Lindstr</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">om V, et al. Prehospital</span></p>
<p style="top:721.7pt;left:326.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">exenatide in hyperglycemic stroke &#x2013; a randomized trial.</span></p>
<p style="top:41.4pt;left:62.4pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Maskery et al.</span></p>
<p style="top:41.4pt;left:535.7pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">29</span></p>


<p style="top:73.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Acta Neurol Scand</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 140: 443&#x2013;448. DOI: 10.1111/</span></p>
<p style="top:84.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ane.13166.</span></p>
<p style="top:95.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">72. McGrath RT, Hocking SL, Priglinger M, et al. Rationale</span></p>
<p style="top:106.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and design of Short-Term EXenatide therapy in Acute</span></p>
<p style="top:117.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">ischaemic Stroke (STEXAS): a randomised, open-label,</span></p>
<p style="top:128.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">parallel-group study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> BMJ Open</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 6: e008203.</span></p>
<p style="top:139.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">73. Muller C, Cheung NW, Dewey H, et al. Treatment with</span></p>
<p style="top:150.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">exenatide in acute ischemic stroke trial protocol: a pro-</span></p>
<p style="top:161.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">spective, randomized, open label, blinded end-point study</span></p>
<p style="top:172.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of exenatide vs. standard care in post stroke hyperglyce-</span></p>
<p style="top:183.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">mia.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Int J Stroke</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 13: 857&#x2013;862.</span></p>
<p style="top:193.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">74. Fei Y, Tsoi M-F and Cheung BMY. Cardiovascular out-</span></p>
<p style="top:204.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">comes in trials of new antidiabetic drug classes: a network</span></p>
<p style="top:215.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">meta-analysis.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Cardiovasc Diabetol</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 18: 112. DOI:</span></p>
<p style="top:226.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">10.1186/s12933-019-0916-z.</span></p>
<p style="top:237.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">75. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in</span></p>
<p style="top:248.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">patients with type 2 diabetes and acute coronary syn-</span></p>
<p style="top:259.9pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">drome.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> N Engl J Med</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2015; 373: 2247&#x2013;2257.</span></p>
<p style="top:270.9pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">76. Marso SP, Daniels GH, Brown-Frandsen K, et al.</span></p>
<p style="top:282.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Liraglutide and cardiovascular outcomes in type 2 diabe-</span></p>
<p style="top:293.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">tes.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> N Engl J Med</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 375: 311&#x2013;322.</span></p>
<p style="top:304.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">77. Marso SP, Bain SC, Consoli A, et al. Semaglutide and</span></p>
<p style="top:315.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cardiovascular outcomes in patients with type 2 diabetes.</span></p>
<p style="top:326.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">N Engl J Med</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 375: 1834&#x2013;1844.</span></p>
<p style="top:337.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">78. Holman RR, Bethel MA, Mentz RJ, et al. Effects of</span></p>
<p style="top:348.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">once-weekly exenatide on cardiovascular outcomes in</span></p>
<p style="top:359.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">type 2 diabetes.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> N Engl J Med</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2017; 377: 1228&#x2013;1239.</span></p>
<p style="top:370.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">79. Hernandez</span></p>
<p style="top:370.0pt;left:114.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">AF,</span></p>
<p style="top:370.0pt;left:137.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Green</span></p>
<p style="top:370.0pt;left:168.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">JB,</span></p>
<p style="top:370.0pt;left:187.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Janmohamed</span></p>
<p style="top:370.0pt;left:246.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">S,</span></p>
<p style="top:370.0pt;left:261.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:370.0pt;left:275.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:381.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Albiglutide and cardiovascular outcomes in patients</span></p>
<p style="top:392.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">with</span></p>
<p style="top:392.0pt;left:91.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">type</span></p>
<p style="top:392.0pt;left:116.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2</span></p>
<p style="top:392.0pt;left:129.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diabetes</span></p>
<p style="top:392.0pt;left:169.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and</span></p>
<p style="top:392.0pt;left:193.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cardiovascular</span></p>
<p style="top:392.0pt;left:258.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">disease</span></p>
<p style="top:403.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">(Harmony</span></p>
<p style="top:403.0pt;left:114.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Outcomes):</span></p>
<p style="top:403.0pt;left:166.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">a</span></p>
<p style="top:403.0pt;left:179.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">double-blind,</span></p>
<p style="top:403.0pt;left:239.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomised</span></p>
<p style="top:414.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">placebo-controlled trial.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 392: 1519&#x2013;1529.</span></p>
<p style="top:425.0pt;left:49.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">80. Gerstein HC, Colhoun HM, Dagenais GR, et al.</span></p>
<p style="top:436.0pt;left:65.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Dulaglutide and cardiovascular outcomes in type 2</span></p>
<p style="top:73.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diabetes</span></p>
<p style="top:73.0pt;left:354.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">(REWIND):</span></p>
<p style="top:73.0pt;left:412.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">a</span></p>
<p style="top:73.0pt;left:426.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">double-blind,</span></p>
<p style="top:73.0pt;left:487.8pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">randomised</span></p>
<p style="top:84.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">placebo-controlled trial.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Lancet</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 394: 121&#x2013;130.</span></p>
<p style="top:95.0pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">81. Husain M, Birkenfeld AL, Donsmark M, et al. Oral sem-</span></p>
<p style="top:106.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">aglutide and cardiovascular outcomes in patients with</span></p>
<p style="top:117.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">type 2 diabetes.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> N Engl J Med</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2019; 381: 841&#x2013;851.</span></p>
<p style="top:127.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">82. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of car-</span></p>
<p style="top:138.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diovascular disease events in patients with type 2 diabetes</span></p>
<p style="top:149.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">prescribed the glucagon-like peptide 1 (GLP-1) receptor</span></p>
<p style="top:160.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">agonist exenatide twice daily or other glucose-lowering</span></p>
<p style="top:171.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">therapies: a retrospective analysis of the LifeLink data-</span></p>
<p style="top:182.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">base.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diab Care</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2011; 34: 90&#x2013;95.</span></p>
<p style="top:193.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">83. Gejl M, Starup-Linde J, Scheel-Thomsen J, et al. Risk of</span></p>
<p style="top:204.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cardiovascular disease: the effects of diabetes and anti-</span></p>
<p style="top:215.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">diabetic drugs &#x2013; a nested case&#x2013;control study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Int J Cardiol</span></p>
<p style="top:226.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2015; 178: 292&#x2013;296.</span></p>
<p style="top:237.9pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">84. Patorno E, Everett BM, Gold&#xfb01;ne AB, et al. Comparative</span></p>
<p style="top:248.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cardiovascular safety of glucagon-like peptide-1 receptor</span></p>
<p style="top:259.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">agonists versus other antidiabetic drugs in routine care: a</span></p>
<p style="top:270.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">cohort study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diab Obes Metab</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 18: 755&#x2013;765.</span></p>
<p style="top:282.0pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">85. Ekstr</span><span style="font-family:AdvP4C4E59,serif;font-size:9.0pt">&#x20ac;</span><span style="font-family:Times New Roman,serif;font-size:9.0pt">om</span></p>
<p style="top:282.0pt;left:355.2pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">N,</span></p>
<p style="top:282.0pt;left:373.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Svensson</span></p>
<p style="top:282.0pt;left:417.4pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">A-M,</span></p>
<p style="top:282.0pt;left:447.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Miftaraj</span></p>
<p style="top:282.0pt;left:488.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">M,</span></p>
<p style="top:282.0pt;left:508.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">et</span></p>
<p style="top:282.0pt;left:523.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">al.</span></p>
<p style="top:293.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Cardiovascular safety of glucose-lowering agents as</span></p>
<p style="top:304.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">add-on medication to metformin treatment in type 2 dia-</span></p>
<p style="top:315.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">betes:</span></p>
<p style="top:315.0pt;left:342.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">report</span></p>
<p style="top:315.0pt;left:373.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">from</span></p>
<p style="top:315.0pt;left:399.9pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">the</span></p>
<p style="top:315.0pt;left:419.1pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Swedish</span></p>
<p style="top:315.0pt;left:457.7pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">National</span></p>
<p style="top:315.0pt;left:499.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Diabetes</span></p>
<p style="top:326.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Register.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diabetes Obes Metab</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2016; 18: 990&#x2013;998.</span></p>
<p style="top:337.0pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">86. Anyanwagu U, Mamza J, Donnelly R, et al. Effect of</span></p>
<p style="top:348.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">adding GLP-1RA on mortality, cardiovascular events,</span></p>
<p style="top:359.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">and metabolic outcomes among insulin-treated patients</span></p>
<p style="top:370.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">with type 2 diabetes: a large retrospective UK cohort</span></p>
<p style="top:381.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Am Heart J</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> 2018; 196: 18&#x2013;27.</span></p>
<p style="top:392.0pt;left:297.6pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">87. Frison V, Simioni N, Marangoni A, et al. Clinical impact</span></p>
<p style="top:403.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">of 5 years of liraglutide treatment on cardiovascular risk</span></p>
<p style="top:414.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">factors in patients with type 2 diabetes mellitus in a real-</span></p>
<p style="top:425.0pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">life setting in Italy: an observational study.</span><span style="font-family:Times New Roman,serif;font-size:9.0pt"> Diabetes Ther</span></p>
<p style="top:435.9pt;left:313.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">2018; 9: 2201&#x2013;2208.</span></p>
<p style="top:41.4pt;left:49.6pt;line-height:10.0pt"><span style="font-family:AdvP7D09,serif;font-size:10.0pt">30</span></p>
<p style="top:41.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP7D0C,serif;font-size:10.0pt">Journal of Cerebral Blood Flow &amp; Metabolism 41(1)</span></p>

</div>
